Bio and Annotated CV

Biography


Mark Hyman Rapaport, MD is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine and Chief of Psychiatric Services at Emory Healthcare in Atlanta, Georgia. Before coming to Emory, he was the Polier Chair and the Chairman of the Department of Psychiatry at Cedars-Sinai Medical Center and a Professor and Vice-chair of the Department of Psychiatry and Behavioral Sciences at the David Geffen School of Medicine at University of California, Los Angeles (UCLA). He also previously served as Director of the Mental Health at the Outpatient Clinical Research Center in the Department of Psychiatry at University of California, San Diego (UCSD) and served as the first Chair of the National Institute on Drug Abuse (NIDA) Clinical Trials Network’s Data Safety Monitoring Board and Chair of its Special Review Committee. He has served on NIH and NIMH Review Committees.

Read more

 

Annotated CV


Mark Hyman Rapaport, M.D.

Emory University School of Medicine
Department of Psychiatry and Behavioral Neurosciences
101 Woodruff Circle, Ste. 4000, Atlanta, GA  30322
(404) 727-8382 telephone   (404) 727-3233 facsimile
mark@markhymanrapaport.com

Current Titles and Affiliations
Reunette W. Harris Professor and Chair, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine 2011

Chief of Psychiatric Services Emory Healthcare, Inc. 2011

Previous Academic and Professional Appointments

2003-2011 Chairman and Professor of Psychiatry and Behavioral Neurosciences Cedars-Sinai Medical Center 2003

2004-2011 The Polier Endowed Chair in Schizophrenia and Related Disorders 2004

2009-2011 Professor of Psychiatry and Behavioral Neurosciences, Cedars-Sinai Medical Center, Los Angeles, CA (Newly instituted academic series)

2003-2011 Vice Chairman and Professor in Residence, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA

1996-2002 Associate Professor in Residence, Department of Psychiatry, University of California, San Diego, CA

1990-1996 Assistant Professor in Residence, Department of Psychiatry, University of California, San Diego, CA

Previous Administrative and/or Clinical Appointments

2001-2003 Director, Corporate Relations, Department of Psychiatry, University of California, San Diego, CA

2001-2003 Associate Director, National Institute of Mental Health – STAR*D Program

1999-2001 Principal Investigator, Director, National Institute of Mental Health – Systematic Treatment Enhancement Program for Bipolar Disorder at University of California, San Diego, CA

1992-1995 Counselor, San Diego Psychiatric Society

1991-2001 Co-Director, Psychopharmacology Research Program, Department of Psychiatry, University of California, San Diego, CA

1991-1992 Acting Medical Director, PTSD Clinical Team, Veterans Affairs Medical Center, San Diego, CA

1991-1992 Chief of Mental Health Clinics, Veteran Affairs Medical Center, San Diego, CA

1990-2002 Director, Mental Health Outpatient Clinical Research Center, Department of Psychiatry, University of California, San Diego, CA

1990-2000 Director, San Diego County/National Institute of Mental Health Depression Awareness Recognition and Treatment (D/ART) Program, San Diego, CA

1990-1997 Consultant, Division of Clinical and Treatment Research, National Institute of Mental Health, Bethesda, MD

1990-1991 Co-Investigator and Associate Director, Coordinating Center of the Consortium on the Genetics of Alcoholism

1988-1989 Senior Staff Fellow, National Institute of Mental Health, Bethesda, MD 1987-1988 Research Coordinator, 4-East, CNB National Institute of Mental Health, Bethesda, MD

1986-1987 Ward Administrator, 4-East, CNB National Institute of Mental Health, Bethesda, MD

1985-1986 Chief Resident, Department of Psychiatry, University of California, San Diego, CA

1975-1976 Administrative Student Intern for the Chancellor, University of California, San Diego, CA

Licensure/Boards

National Board of Medical Examiners, 1983
Georgia Medical License—Active 2011
California Medical License—Active – 1983
Maryland Medical License —Inactive 1986

Specialty Boards

The American Board of Psychiatry and Neurology, 1987

Education

1973-1977 BA, Biology (Cum Laude) Revelle College, University of California, San Diego

1977-1978 Department of Biology, University of California, San Diego, CA

1978-1982 MD University of California, San Diego, School of Medicine, San Diego, CA

Post Graduate

1982-1983 Internship Long Beach VA-UCI, Internal Medicine, Long Beach, CA

1983-1986 Residency University of California, San Diego, CA, Psychiatry, San Diego, CA

1985-1986 Research Fellow Department of Psychiatry, University of California, San Diego, San Diego, CA

1986-1989 Medical Staff Fellow National Institute of Mental Health, Bethesda, MD

1989-1990 Guest Researcher Clinical Neuroscience Branch, NIMH, Bethesda, MD

Government Service
1991-2002 Staff Physician, Veterans Affairs Medical Center, San Diego, CA

1989-1990 Chief, Psychopharmacology and Somatic Treatments Program Schizophrenia Research Branch, Division of Clinical Research, National Institute of Mental Health, Rockville, MD

Leadership Roles

National and International

2013 Treasurer, ASCP

2013 Member-Elect, ADAA Scientific Council

2012 Member. NCDEU Steering Committee

2012 Fellow, American College of Neuropsychopharmacology

2012 Treasurer-elect, ASCP

2011 Member, Trauma Research Award Committee, The American College of Psychiatrists

2011-Current Chair, NIDA, Protocol Review Board, CTN0051

2011-Current ASCP/CME Program Committee

2011-Current ASCP/Maintenance of Certification (MOC) Committee

2011-Current Chair,ASCP New Investigators Award Program

2011-Current NIMH DSMB Member, PROACTIVE Study Relapse Monitor Board

2011-Current DSMB Member, AARQ “CHOICE” Trial

2011-Current Scientific Advisory Board, the Depressive and Bipolar Disorder Alternative Treatment Foundation

2010-Current Vice-Chair, Council on Medical Education and Lifelong Learning, American Psychiatric Association

2010 Chair, NIDA Special Review Committee

2010-2011 APA/NIMH Vestermark Award Selection Committee

2010-Current Representative from the American Psychiatric Association to the Council of Academic Societies of American Association of Medical Colleges (AAMC)

2009-Current Council on Medical Education and Lifelong Learning, American Psychiatric Association

2009-Current Vice-Chair, World Psychiatric Association Section on Immunology and Psychiatry

2009 Planning Committee, 50th Anniversary NCDEU Meeting

2009-2012 Member, Committee on the Education Award, The American College of Psychiatry

2009-2012 Education and Training Committee, American College of Neuropsychopharmacology

2008-2009 DSMB Member “Improving Care for Adolescent Suicide Attempters,” PI Joan Asarnow

2008-2009 DSMB Member, “Reducing Health Risk Behavior & Improving Adolescent Health, Pl Joan Asarnow

2007-Current Board of Directors, American Society for Clinical Psychopharmacology

2007-2009 Chair, CME/Lifelong Learning Committee, American Psychiatric Association

2007 NAMI Research Award Selection Committee

2005 DSMB Member, “Selegiline Patch for Treatment of Nicotine Dependence, PI Joe Klein

2005 Faculty of 1000 Medicine

2005-2007 Continuing Medical Education and Lifelong Learning Committee, American Psychiatric

2004-2009 DSMB Member, “Sleep Apnea and Hypertension: the Role of the SNS,” PI Joel Dimsdale

2004-2007 Founding Member, International Society for CNS Clinical Trials and Methodology

2004-2007 Executive Committee, International Society for CNS Clinical Trials and Methodology

2004-2007 Liaison with International Society for CNS Clinical Trials and Methodology and International Society for CNS Drug Development

2004-2006 Chair, Subcommittee on Psychiatric Self-assessment, American Psychiatric Association

2004-2005 Rand Expert Consensus Panel on Depression and Asthma

2002-2009 Annual Meeting Program Committee, International Society for CNS Drug Development

2002-2009 Committee on Continuing Medical Education, American Psychiatric Association

2002-2008 Scientific Committee, International Society for CNS Drug Development

2000-2002 Chair, Data Safety Monitoring Board (DSMB), Clinical Trials Network, National Institute on Drug Abuse

2001 Chairman, 7th Experts Meeting on Psychoimmunology, Session 4

2000 Chair, Special Review Committee, NIDA Clinical Trials Network

1999-2006 Chairperson, Subcommittee on Self-Assessment, Planning Subcommittee, Council on Medical Education and Career Development, American Psychiatric Association

1999 The Expert Consensus Consortium Survey: “Guidelines for Antidepressant Medication in Primary Care”

1997 Consultant to NIMH for the Development of the Hypericum RFP

1997-Current Section of Immunology and Psychiatry, World Psychiatric Association

1997-2007 Scientific Advisory Board, Integrated Neuroscience Consortium

1998-1999 Vice Chairperson, PKSAP Planning Subcommittee, Council on Medical Education and Career Development, American Psychiatric Association

1995-1996 Examiner, American Board of Psychiatry and Neurology

1992-Current Co-Chair, New Investigators Workshop, NCDEU

1991-Current Chair, New Investigators Program, NCDEU

1990-1998 Reviewer, “New Research” Program, American Psychiatric Association

1990-2009 Scientific Program Committee, NCDEU

 

Regional and State

2011-Current Board Member, Georgia Psychiatric Physicians Association

2004-2010 Councilor, West Coast College of Biological Psychiatry

2004 President, West Coast College of Biological Psychiatry

2003 President-Elect, West Coast College of Biological Psychiatry

2001 Vice-President, West Coast College of Biological Psychiatry

1999-2001 Chair, Credentials Committee, West Coast College of Biological Psychiatry

1999-2000 Chair, Program Committee, West Coast College of Biological Psychiatry

1994-2001 Chair, Continuing Medical Education Committee, San Diego Psychiatric Society

1994-1995 Scientific Program Committee, California Psychiatric Association

1994-1995 Co-Chair, Scientific Program Committee, California Psychiatric Association Annual Meeting

1993-1997 Co-Chair, Program and CME Committee, San Diego Society of Psychiatry

1993-1994 Co-Chair, Program Committee, San Diego Society of Psychiatry

1992-1995 Counselor, San Diego Psychiatric Society

1991-1994 Program Committee, California Psychiatric Association Society

1991-1994 Board of Directors, San Diego Mental Health Association

1990-1996 Director, NIMH D/ART Program for San Diego Region

1990-1993 Chair, Youth & Schools Committee D/ART

 

Institutional

2013 Co-Chair, Ad Hoc Committee on Strategic Partnerships between Woodruff Health Sciences and Industry

2013 Member, Yerkes Director Search Committee

2013 Member, Committee for Review on Tenure for Woodruff Health Sciences Center

2013 Member, Search Committee–Rollins Professor & Chair, Department of Behavioral Sciences and Health Education, RSPH-EU

2012 Member, Search Committee – Associate Vice President for Research Administration Service Centers, EU

2012 Member, GME Strategic Plan Steering Committee. EUSM

2012 Member, Business Practice Committee (BPI), EHC

2012 Member. BITC/CSI Oversight Committee, EHC

2012 Member, Cancer Prevention and Control Research Program, WCI

2012 Member, School of Medicine Dean Search Committee. EUSM

2012 Member, Family Medicine Chair Search Committee, EUSM

2012 Chair, BITC/CSI Consolidation Advisory Committee, EUSM

2011 Member. Emory Healthcare Quality Council, Emory Healthcare

2011 Member, Academic Clinical Integration Committee, WHSC, EUSM

2011 Member. Executive Committee, Neuroscience Institute, Emory EUSM

2011 WHSC – Research Advisory Council, Emory University School of Medicine

2011 CS-Link Clinical Systems Informatics Committee, Cedars-Sinai Medical Center

2011 Integrative Medicine Strategic Planning Taskforce

2010 CS Medicine Steering Committee, Cedars-Sinai Medical Center

2009-2011 Healthcare Ethics Internal Advisory Board Committee, Cedars-Sinai Medical Center

2008-2011 CS-Link Medical Staff Executive Committee, Cedars-Sinai Medical Center, Los Angeles

2008-2011 Graduate Program Steering Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2007-2011 CS-Link Executive Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2007-2009 Chair of Chairpersons Group, Cedars-Sinai Medical Center, Los Angeles, CA

2007-2009 Executive Committee, Board of Directors, Cedars-Sinai Medical Center (Ex Officio), Los Angeles, CA

2007-2009 Medical Policy Committee, Board of Directors, Cedars-Sinai Medical Center, Los Angeles, CA

2006-2011 Clinical Care Quality Improvement Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2005 Subcommittee on Clinical Care Strategies, Strategic Planning Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2005 Subcommittee on Community Activity and Philanthropy Strategic Planning Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2005 Strategic Planning, Executive Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Chair, Psychiatry Performance Improvement Committee (DPIC), Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Chief of Staff Advisory Committee (COSAC), Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Executive Management Group (EMC), Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Academic Partnership Committee, UCLA Department of Psychiatry and Biobehavioral Science, Los Angeles, CA

2003-2011 Medical Staff Leadership Group (MLG), Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Medical Executive Committee (MEC), Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Medical Center Quality Council, Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Medical Staff Quality Improvement Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Medical Center Management Group, Cedars-Sinai Medical Center, Los Angeles, CA

2003-2011 Serious Adverse Events (SAE) Oversight Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2003 Blue Ribbon Committee on Faculty Appointments, UCLA Department of Psychiatry and Biobehavioral Science, Los Angeles, CA

2003 Grant & Funding Accounting/Grant & Contract Services (GFA/GCS), Cedars-Sinai Medical Center, Los Angeles, CA

2003 Physician/Medical Center Compact Committee, Cedars-Sinai Medical Center, Los Angeles, CA

2002-2003 Planning and Budget Subcommittee on Campus Budget, UC San Diego, San Diego, CA

2002-2003 Vice Chair, Human Subjects Protection Committee, UC San Diego School of Medicine, San Diego, CA

2002-2003 Senior Executive Committee Psychopharmacology Research Initiatives, Center of Excellence, UC San Diego, San Diego, CA

2002-2003 Co-Director, Psychopharmacology Research Initiatives, Center Of Excellence, UC San Diego, San Diego, CA

2001-2002 Performance Improvement Committee, San Diego Veterans Affairs Medical Center, San Diego, CA

2001-2002 Chair, Psychiatric Service Performance Improvement Committee, San Diego Veterans Affairs Medical Center, San Diego, CA

1999-2000 Search Committee for the Division Director for Biostatistics, Department of Family Medicine, UC San Diego, San Diego, CA

1997-2002 Institutional Review Board, UC San Diego, San Diego, CA

1997-2002 Chair, Medical Records Committee, San Diego Veterans Affairs Medical Center, San Diego, CA

1997-2002 National Institute of Mental Health Psychobiology and Psychopharmacology Fellowship Advisory Committee, UC San Diego, San Diego, CA

1997-1999 Admissions and Promotions Committee, Department of Psychiatry, UC San Diego, San Diego, CA

1997-1998 Psychiatric Resident Research Committee, San Diego Veterans Affairs Medical Center, San Diego, CA

1996-2000 Veterans Affairs Electronic Medical Records Committee, San Diego Veterans Affairs Medical Center, San Diego, CA

1996-1999 Residency Selection Committee, Department of Psychiatry, UC San Diego, San Diego, CA

1995-1999 Institutional Review Board, Veterans Affairs Medical Research Foundation, San Diego Veterans Affairs Medical Center, San Diego, CA

1995-1996 Strategic Planning Committee for Research Development, San Diego Veterans Affairs Medical Center, San Diego, CA

1994-2002 Standing Dean’s Advisory Committee on Clinical Trials, UC San Diego, San Diego, CA

1993-2002 Medical Records Committee, San Diego Veterans Affairs Medical Center, San Diego, CA

1993-1996 Quality Assurance Committee, Psychiatric Service, San Diego Veterans Affairs Medical Center, San Diego, CA

1991-1995 Bio-Ethics Committee, UC San Diego, San Diego, CA

1990-2002 Scientific Advisory Committee, UC San Diego Mental Health Clinical Research Center, San Diego, CA

Grant Reviews

Reviewer, ZAT1-HS-11Study Section, NCCAM, NIH, 2013

External Reviewer, National Research Foundation of South Africa, 2012

Ad Hoc Reviewer, NIH/CSR: 2012

External Reviewer, Medical Research Council of United Kingdom: 2011

Chair, NIDA Protocol Review Board: 2011

Chair, NIDA Special Review Committee: 2010

External Reviewer, Canadian Institutes of Health Research: 2009

ITMA NIH Review Committee: 2005-2008

NRRC Special Review Committee (For CTSA Review): 2007

Chair, NIDA Special Review Committee: 2005

Reviewer, NCCAM Special Review Committee: 2003

Chair, NIMH Special Review Committee: 2000, 2001, 2002, 2004, 2009

Chair, NIDA Special Review Committee: 2000

Member, NIDA Special Review Committee: 1999, 2000

Ad Hoc VA Merit Board Reviewer: 1995, 1996

Ad Hoc Reviewer, NIMH: 1989, 1994, 1995- 2007

Editorships and Editorial Boards

Editorships

2002-Current Founding Co-Editor in Chief, FOCUS: “A Journal for Lifelong Learning in Psychiatry,” APPI Press

 

Editorial Board Appointments

2012 Editorial Board, “Journal of Addictive Behaviors, Therapy & Rehabilitation

2012-Current Editorial Board, “Shanghai Archives of Psychiatry”

2011-Current Editorial Board, “Innovations in Clinical Neuroscience”

2009-Current Editorial Board, “CNS Spectrums”

2009-Current Editorial Board, “Journal Clinical Psychiatry”

2009-Current Editorial Board, “Depression Research and Treatment”

2008-Current Editorial Board, “CNS Neuroscience and Therapeutics”

2006-2010 Editorial Advisory Board, “Psychiatry”

2004 Advisory Board, “Medworks Media Journal C-3”

2004 Guest Editor, “Mental Fitness towards a New Understanding of Schizophrenia”

2004 Editor, WPA Series: “Burden of Phobias: Focus on Health-Related Quality of Life”

2003 Advisory Board, “Handbook of Bipolar Disorder”

1996-1998 Editorial Board, “Depressive Disorders Index & Review

1989-1998 Associate Editor, “Psychopharmacology Bulletin Current Drugs”

1996 Advisor, “Handbook of Psychiatric Measures and Outcomes,” American Psychiatric Association

 

Manuscript Reviewer

ACNP-NIMH “Clinical Evaluation of Psychotropic Drugs: Principles and Guidance”, 1992

Acta Psychiatrica Scandinavica, 1994-Current

American College of Physicians–Review of GAD

American Journal of Medicine, 1998

American Journal of Geriatric Psychiatry, 1997-Current

American Journal of Psychiatry, 1988-Current

Anxiety, 1992-1996

Anxiety and Depression, 1996-Current

Archives of General Psychiatry, 1989-Current

Biological Psychiatry, 1998-Current

Brain, Behavior and Immunity, 1994-1996

CNS Drugs, 1998-2002

Comprehensive Psychiatry, 2008-Current

Depressive Disorders: Index & Reviews, 1994-1996

International Journal of Neuropsychopharmacology, 2000-Current

Journal of Affective Disorders, 1996-Current

Journal Clinical Psychiatry, 1998-Current

Journal of Emergency Medicine, 1993

Journal of Neuronal Transmission, 1994

Journal of Psychiatric Research, 1997-Current

Molecular Psychiatry, 2002-Current

Neuropsychopharmacology, 1996-Current

New England Journal of Medicine (book review)

Progress in Neuro-Psychopharmacology & Biological Psychiatry, 1998-2001

Psychiatric Neurogenetics, 2000-2007

Psychiatry Research, 1996-Current

Psychoneuroendocrinology 2013

Psychopharmacology, 1998-2000

Psychopharmacology Bulletin, 1998-2000

Psychosomatic Medicine, 1996-2007

The Review of Experts on Pharmacotherapy, 2002-2004

Honors and Awards
2011 Integrative Medicine Award, Prevention Magazine

2010-Current The Global Directory of Who’s Who (Top Doctors)

2007 Lifetime Achievement Award, NCDEU

2006 Visiting Professor, Shanghai Mental Health Center, Shanghai, China

2004 Distinguished Fellow, American Psychiatric Association

2003 Fellow, Collegium Internationale Neuro-Psychopharmacologicum (CINP)

2001 Teacher of the Year, UC San Diego Department of Psychiatry

2000 Clinician of the Year, San Diego Psychiatric Society

2000 Visiting Professor, University of New Mexico

2000 Fellow, American Psychiatric Association

1997 Distinguished Speaker, Third International Experts Conference on Psychiatry and Immunology, Munich, Germany

1997 Visiting Professor, State University of New York, Buffalo, NY

1996-Current Marquis Who’s Who

199 Visiting Professor, Dartmouth University

1994 Visiting Professor, Ludwig-Maximilans-University, Munich

1986 Judd Award for Research Excellence during Residency

Society Membership
Vice Chair of the Section on Immunology and Psychiatry, 2009-Current

Association for Academic Psychiatry, 2009

American Association of Chairs of Departments of Psychiatry, 2008-Current

American College of Neuropsychopharmacology, 2007-Current

American College of Psychiatry, 2004–Current

International Society for CNS Clinical Trials and Methodology, 2004–2007

Southern California Psychiatry Society, 2003-2011

San Diego Psychiatric Society, 1990-2003 International Society for CNS Drug Development, 2002-Current

West Coast College of Biological Psychiatry, 2000–2009

President, 2004

President-Elect, 2003

Collegium Internationale Neuro-Psychopharmacologicum, 2000-Current

American Society of Clinical Psychopharmacology, 1999-Current

Council, 2008-Current Society of Biological Psychiatry, 1998-Current

World Psychiatric Association Section on Immunology and Psychiatry, 1996-Current

Anxiety Disorders Association of America, 1994-Current

The Psychiatric Research Society, 1994-Current Psychoneuroimmunology Society, 1992-1994

American Psychiatric Association, 1984-Current

National or International Conferences-Chair

2013 Co-Chair, Poster Presentations, 11th World Congress of Biological Psychiatry, WFSBP, Kyoto, Japan, “Liaison Psychiatry and other topics”

2013 Co-Chair, FOCUS Live, American Psychiatric Association, 166th Annual Meeting, San Francisco, CA, “Depression”

2013 Co-Chair, FOCUS Live, American Psychiatric Association, 166th Annual Meeting, San Francisco, CA, “Child Psychiatry”

2013 Co-Chair, 53rd Annual NCDEU Meeting, Hollywood, FL, New Investigators Workshop 2012 Co-Chair, 52nd Annual NCDEU Meeting, Phoenix, AZ, New Investigators Workshop

2012 Co-Chair, FOCUS Live, American Psychiatric Association, 165th Annual Meeting, Philadelphia, PA, “Anxiety.”

2012 Co-Chair, FOCUS Live, American Psychiatric Association, 165th Annual Meeting, Philadelphia, PA, “Schizophrenia.”

2011 Chair, Education Workshop, American College of Neuropsychopharmacology

2011 Annual Meeting, Kona, Hawaii, “Teaching Innovations”.

2011 Co-Chair, FOCUS Live, American Psychiatric Association, 164th Annual Meeting, Honolulu, Hawaii, “Treatment Resistant Disorders”.

2011 Co-Chair, FOCUS LIVE, American Psychiatric Association, 164th Annual Meeting, Honolulu, Hawaii, “Substance Abuse”.

2011 Co-Chair, 51st Annual NCDEU Meeting, Boca Raton, FL, New Investigators Workshop 2010 Chair, Poster Walk II, 18th European Congress of Psychiatry, Munich, Germany

2010 Co-Chair, FOCUS Live, American Psychiatric Association, 163rd Annual Meeting, New Orleans, LA, “Psychotherapy”

2010 Co-Chair, FOCUS Live, American Psychiatric Association, 163rd Annual Meeting, New Orleans, LA, “Genetics and Genomics”

2010 Co-Chair, FOCUS Live, American Psychiatric Association, 163rd Annual Meeting, New Orleans, LA, “Sleep and Sex:”

2010 Chair, Symposium American Psychiatric Association, 163rd Annual Meeting, New Orleans, LA, “Basic Science in Psychiatry: A Move toward Translational Medicine”

2010 Co-Chair, 50th Annual NCDEU Meeting, Boca Raton, FL, New investigators’ Workshop

2010 Co-Chair, 50th Annual NCDEU Meeting, Boca Raton, FL, “Enhancing Precision in Clinical Trials XII Workshop”*

2010 Co-Chair, 50th Annual NCDEU Meeting, Boca Raton, FL, New Investigator Graduate Symposium, “Translational Perspectives on Treatment Development”

2010 Co-Chair, 49th Annual ACNP Meeting, Miami Beach, FL, ACNP Teaching Neuropsychopharmacology Session, “New Developments in Psychopharmacology Education in Lean Times”

2010 Chair, 49th Annual ACNP Meeting, Miami Beach, FL, “Omega-3 Fatty Acids and Depression from Cellular Mechanisms to Clinical Care”

2009 Co-Chair, FOCUS Live, American Psychiatric Association 162nd Annual Meeting, San Francisco, CA, “Geriatric Psychiatry”

2009 Co-Chair, FOCUS Live, American Psychiatric Association 162nd Annual Meeting, Francisco, CA “PTSD and Disaster”

2009 Co-Chair, FOCUS Live, American Psychiatric Association 162nd Annual Meeting, San Francisco, CA “Panic and Social Anxiety Disorder

2009 Co-Chair, 49th Annual NCDEU Meeting, Hollywood, FL, New Investigator’s Workshop

2009 Chair, 49th Annual NCDEU Meeting, Hollywood, FL, “Enhancing Precision in Clinical Trials XI Workshop”

2009 ACNP 48th Annual Meeting, Hollywood, FL, Teaching Neuropsychopharmacology Session, “The Impossible Dream:” Keeping Up with Clinical Neuroscience and Psychopharmacology,

Circa 2010, “The Crisis for Clinicians”

2008 Co-Chair, FOCUS Live Session, APA Annual Meeting, Washington, DC: “Schizophrenia”

2008 Co-Chair, FOCUS Live Session, APA Annual Meeting, Washington, DC: “Major Depressive Disorder”

2008 Co-Chair, NCDEU, 48th Annual Meeting, Phoenix, AZ: New Investigator Workshop

2008 Co-Chair, NCDEU 48th Annual Meeting, Phoenix, AZ: “Enhancing Precision in Clinical Trials X Workshop”

2008 Chair, Symposium, World Psychiatric Association, Psychoneuroimmunology (PNI) Workshop, Seeon, Germany: “Anti-inflammatory Medication in Major Psychiatric Disorders: Role of COX-2 Inhibition”

2007 Chair, Tucson, AZ: West Coast College Resident Mentoring Program

2007 Chair Symposium APA, San Diego, CA: “Integrating Alternative Health Approaches into the Care of Our Patients: Evidence about the Actions of Exercise, Massage, and Acupuncture”

2006 Symposium Chair, 2nd Annual Scientific Congress, The International Society for CNS Clinical Trials and Methodology: “Treatment Resistance: New Designs and Regulatory Opportunities”

2006 Symposium Chair, APA Annual Meeting, Toronto, Canada: “Bipolar Disorder: Creating a Consensus from Science to Public Policy”

2006 APA Annual Meeting, Toronto, Canada: “A Rational Approach for the Longitudinal Pharmacologic Management of Patients with Bipolar Disorder: An Argument for Changing Public Policy”

2006 Co-Chair, FOCUS Live, APA Annual Meeting, Toronto, Canada: “Personality Disorders”

2006 Co-Chair, FOCUS Live, APA Annual Meeting, Toronto, Canada: “Eating and Sexual Disorders”

2006 Co-Chair, FOCUS Live, APA Annual Meeting, Toronto, Canada: “Psychotherapy”

2006 Symposium Chair, APA Annual Meeting, Toronto, Canada: “New Strategies to Address Anxiety and Resistant Somatic Symptoms”

2005 Chair, APA Annual Meeting, Symposium, Atlanta, GA: “Anxiety Disorders: Understanding the Interconnection between Emotional and Physical Symptoms”

2005 Co-Chair, FOCUS Live, APA Annual Meeting Atlanta, GA: Major Depressive Disorder

2005 Co-Chair, FOCUS Live, APA Annual Meeting, Atlanta, GA: “Psychosomatic Medicine: Consultation Liaison Psychiatry and Beyond”

2005 Co-Chair, FOCUS Live, APA Annual Meeting, Atlanta, GA: “Child and Adolescent Psychiatry”

2005 Chair, New Investigators Workshop, Boca Raton, FL: NCDEU 45th Annual Meeting

2005 Chair, NCDEU Annual Meeting, Boca Raton, FL: “Enhancing Precision in Clinical Trials VIII Workshop”

2005 Chair, ISCTM, Montreal, Canada: “Difficulties in Establishing Long-Term Efficacy for Psychotropic Drugs: Common Methodological Issues”

2005 ISCTM, Montreal, Canada: “Presentation: Methodological Challenges in Long-TermTrials: An Academics Perspective”

2005 University of South Carolina Annual Psychopharmacology Update: “An Update on the Treatment of Resistant Depression”

2004 Chair, Symposium, APA Annual Meeting, New York, NY: “Emerging Treatment Options in Treatment-Resistant Mood and Anxiety Disorders”

2004 FOCUS Live, APA Annual Meeting, New York, NY: “Forensic and Ethical Issues in Psychiatry“

2004 Co-Chair, FOCUS Live, APA Annual Meeting, New York, NY: “PTSD and Anxiety Disorders: Test Your Knowledge”

2004 Co Chair, FOCUS Live, APA Annual Meeting, New York, NY: Lauriello J, Hales DJ, Rapaport MH: “Schizophrenia: Test Your Knowledge

2004 Chair, NCDEU Annual Meeting, Workshop Session, Boca Raton, FL: “Enhancing Precision in Clinical Trials VII”

2004 Co-Chair, NCDEU Annual Meeting, Boca Raton, FL: New Investigator’s Workshop

2004 NCDEU Annual Meeting, Boca Raton, FL: “Quality Of Life Assessments: Can They Differentiate Drug from Placebo?”

2003 Grand Rounds, Department of Psychiatry, Cedars-Sinai Medical Center, Los Angeles, CA: “Quality of Life and Mood and Anxiety Disorders”

2003 Chair Symposium American Psychiatric Association 156th Annual Meeting, San Francisco, CA: “Polypharmacy in the Treatment of Major Depression”

2003 Co-Chair, American Psychiatric Association Annual Meeting, San Francisco, CA: “Focus Live: Bipolar Disorder”

2003 Co-Chair, American Psychiatric Association Annual Meeting, San Francisco, CA: “Focus Live: Substance Abuse”

2003 Chair, NCDEU Annual Meeting, Workshop Session, Boca Raton, FL: Enhancing Precision in Clinical Trials VI

2003 Co-Chair, NCDEU Annual Meeting, Boca Raton, FL: New Investigators Workshop 2002 Symposium Chair, American Psychiatric Association

2002 Annual Meeting, New York, NY: “Adolescence: The Tumultuous Years” 2002 Co-Chair, NCDEU, Scottsdale, AZ: New Investigators Workshop

2002 Chair, NCDEU, Workshop, Scottsdale, AZ: “Increasing Precision in Clinical Trials V”

2002 NCDEU, Scottsdale, AZ: “Using Quality of Life Measures to Differentiate Drug from Placebo”

2002 Chair, NCDEU, Workshop, Scottsdale, AZ: “Use of New Technologies in Clinical Trials”

2002 Chair, NCDEU Panel, Scottsdale, AZ: “Novel Pharmacotherapies for Depression”

2001 Course Director and Lecturer, Hilton Torrey Pines Grande Hotel, San Diego, CA: “Treatment Refractory Depression”

2001 Co-Chair, NCDEU: “New Investigators Program”

2001 Chair, NCEDU: “Increasing Precision in Clinical Trials Workshop”

2001 NCDEU New Investigators’ Workshop: “The Treatment of Chronic Insomnia Drug Indications, Chronic Use and Abuse Liability”

2001 NCDEU Workshop: “Advances for Enhancing Precision in Clinical Trials IV”

2001 ACNP Session: “The Teaching of Psychopharmacology”

2000 Course Director, UCSD CME Symposium, Wyndham Emerald Plaza Hotel, San Diego, CA: “Diagnosis and Psychopharmacological Interventions with the New Generation of Antidepressants for Depression

2000 Chair, Society of Biological Psychiatry Meeting, Chicago, IL Workshop: “The Interaction between the Immune System and Psychiatric Disorders”

2000 Co-chair, NCDEU, Boca Raton, Florida Workshop: “Enhancing Precision in Clinical Trials III”

1999 Chair, ADAA’s 19TH National Conference Symposium, San Diego, CA: “Panic Disorder: Impact on Patient Care”

1999 Co-chair, NCDEU, Boca Raton, Florida Workshop: “Enhancing Precision in Clinical Trials II”

1999 Grand Rounds, Twin Towers Correctional Institute, Los Angeles, CA: “New Advances in the Treatment of Resistant Depression”

1998 Co-chair, NCDEU, Boca Raton, Florida Workshop: “Enhancing Precision in Clinical Trials”

1998 Co-chair, PRISM Workshop: “The Use of Placebo Lead-ins and Placebo-Controlled Trials”

1997 Invited participant, ACNP: Study Group Assessing Treatment Outcomes in Panic Disorder

1997 Symposium Co-Chair, NCDEU, Boca Raton, Florida: “A Comparison of New Psychopharmacological Treatments for Panic Disorder”

1997 Faculty participation, Biological Psychiatry Seminar for New Investigators, San Diego, CA

1996 Symposium Co-Chair, Boca Raton, Florida: “Depressive Symptom Disorders”

1995 New Investigators Program NCDEU: “How to Write a Paper for Publication”

Research

I have had a number of research foci over the years, these include: human psychoneuroimmunology, psychopharmacology research, clinical trials methodology quality of life and complementary and alternative medicine.

Grant Support

 

Active Support

2008-2013 NIMH 5R01MH085542-03 “International Cohort Collection for Bipolar Disorder, (Jordan Smoller, PI), Total costs” $98,310

2008-2013 NIMH 1R0-1MH085548-0 3: “The Genomic Psychiatry Cohort,” Site PI, (Carlos Pato PI), Total costs $ 286,270

2010-2014 NCCAM 1R-21AT004208: “Efficacy of Massage Therapy in the Treatment of Generalized Anxiety Disorder (GAD),” PI, Total costs $650,000

2012-2014 NIMH HHS-NIH-MH-2010-024 “Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS),” PI of Emory Subcontract, Total costs $358,045.

2012-2017 NIMH 1K23MH098014-01: “A Potential State and Relapse Predictive Marker in Schizophrenia (Brian Miller, PI), Total costs $170,600

2013-2018 NIMH MH100023-01: “Silvio O. Conte Center for Oxytocin and Social Cognition,” (Larry Young, PI), Total costs $1,161,874

2013-2015 NCCAM 1R-21AT007090-01A1: “Efficacy of Swedish Massage Therapy on Cancer Related Fatigue in Cancer Survivors,” PI, Total costs $363,138 2

2013-2015 NIMH R43MH097370-01: “A Peripheral Diagnostic Biomarker for Major Depressive Disorder,” (Scheckter, PI), Total costs 326,132

 

Pending Support

2014-2019 NIH/NCCAM: “The Emory Center of Excellence for Research on Massage”: P01 – PI: Rapaport, PI Database and Biostatistics Core: Schettler) $1,250,000

2013-2016 NIH/NCCAM/NIMH 1R34MH101434-01: “1/3 Massage for Depression: Efficacy and Mechanisms”, PI, $475,000

2014-2019 NIMH R01MH101330-01: “Immune Activation, Genetics and Schizophrenia,” $892,002

2014-2019 NIMH 1R25MH101079-01:”Emory Psychiatry Clinical Scientist Training Program (CSTP)” Kerry Ressler, PI), $968,142

2013-2015 NIH/NCCAM: “Neurohormonal Response to Spinal Manipulation – A Preliminary Study on Oxytocin System Activity” Drs. Goertz/Xia, PI) $275,000

2013-2018 NIMH “Pharmacological vs. Behavioral Early Intervention to Prevent PTSD in Those at Risk”, Barbara Rothbaum, PI, $3,627,516

 

Previous Support

2008-2013 NIMH 5R01MH085542-03: “International Cohort Collection for Bipolar Disorder” (Jordan Smoller, PI), Total costs $98,310

2006-2012 NIMH 5R0-1MH073765-05: “Omega-3 Fatty Acids for Treatment of Major Depressive Disorder,” PI, Total costs $1,373,463

2011-2016 1956006143A1: “UCLA Clinical and Translational Science Institute,” (Steven Dubinett, PI), Total costs $90,354,250

2006-2009 NCCAM 5R-21AT002751-03: “A Model for the Mechanism of Action of Massage,” PI, Total costs $613,002

2001-2006 NIMH/NCCAM 5R0-1MH61757: “Pharmacotherapy for Minor Depression,” PI, Total costs $957,580

2001-2003 Stanley Foundation 010321: “A Prospective Double-Blind, Placebo-Controlled, Add-On Trial in the Treatment of Schizophrenia,” PI, Total Costs $400,000

2001-2002 NIMH N01MH90003: “Sequenced Treatment Alternatives to Depression (STAR*D),” Co-Director, (Sidney Zisook PI) Total costs $400,000

1999-2001 NIMH 98-DS-001: “Systematic Enhanced Treatment Program for Bipolar Disorder,” PI, Total costs $300,000

1999-2000 NARSAD Independent Investigator Award: “The Longitudinal Outcome of Schizophrenic Patients with Immune and Motor Dysfunction,” PI, Total costs $100,000

1997-2002 R-29MH49746: “Schizophrenia and Immune Activation,” PI, Total costs $650,000

1997-2002 5P30MH49671: “Psychosis and Antipsychotics in Late Life,” Co-Investigator, (Dilip Jeste PI), Total costs $5,000,000

1997-2001 MH30914-21: “Psychobiological Studies of Psychiatric Disorders,” Co-Investigator and Director of the Outpatient Component of the Center, (Chris Gillin PI), Total costs $4,000,000

1996-1999 VA Merit Award: “Immune Activation and Schizophrenia,” PI, Total costs $450,000

1992-1994 Volkswagen Stiftung: “Immunological Changes in Schizophrenia,” US PI, (Norbert Mueller German PI), Total costs $200,000

1991-1996 MH30914-16: “Psychobiological Studies of Psychiatric Disorders,” Co-Investigator and Director of the Outpatient Component of the Center, (Chris Gillin PI), Total costs $4,000,000

Funds Raised from Philanthropy

 

Endowed Chairs

The Polier Endowed Chair in Schizophrenia and Related Disorders, 2004

The Steve Gordon Family Endowed Chair in Memory Disorders, 2006

The Lincy/Heyward-Moynihan Endowed Chair in Addiction Medicine, 2006

The Mark and Barbara Klein Chair in Psychiatry, 2013

 

Endowed Funds

Research Endowment: $2.25 million, 2003-2010

Operations Endowment: $ 4 million, 2003-2010

Academic Endowment: $7.75 million, 2003-2010

Teaching and Mentoring

2013 Focus: “Major Depressive Disorder Maintenance of Certification (MOC) Workbook”

 

Undergraduate Lectures

1996 Undergraduate Introduction to Psychiatric Disorders: Invited Lecture for an Advanced Neuroscience Course

1997 Undergraduate Introduction to Psychiatry: Invited Lecture, Introduction to Clinical Medicine for Undergraduates Course.

 

Medical Student Teaching

2003 Topics and Advances in Internal Medicine: Invited Lecturer for Department of Medicine, UCSD School of Medicine

2003 The Presentation of Minor Depression and Spectrum Forms of Depression in Consultation Liaison

1990-2002 MSIII Introduction to Clinical Management of Schizophrenia: Introductory into Clinical Management of Schizophrenia (given every 6 to 8 weeks).

1997-1999 Social & Behavioral Sciences Psychopathology Course MSII Small Group Leader Introduction to Psychiatry: Social Behavioral Sciences Course

 

Residency Teaching

1990-2002 Outpatient Clinical Case Conferences (PGY-III Residents)

1990-2002 Co-leader, weekly diagnostic case conference for Research Fellows

1990-2000 Fellowship teaching of weekly clinical supervision with all Fellows who participated in the Mental Health Clinical Research Center

1990-2002 PGY-III Advanced Psychopharmacology Schizophrenia I, II

1991-2002 Resident Teaching, PGY-II Introduction to Clinical Diagnosis

1996-1999 Readings in Psychiatry Seminar (Monthly – PGY-II, PGY-IV)

1999-2000 Readings in Psychiatry Seminar (Monthly – PGY-II, PGY-IV) – In coordination with John Kelsoe and Ronald Kuczenski

2000-2001 Journal Club (PGY-II, PGY-IV)

2000-2002 Review Seminar for PGY-IV Residents preparing for Part 1 of the Psychiatry National Board Examination (12-15 weeks/year)

2003-2007 Leader, weekly Patient Evaluation Team (PGY-III, Social Work, Interns, Psychology Interns)

2004-2007 Supervisor, PGY-II Research Residents, Research Fellows, Research Chief Resident

2006-2011 Mentor for the Residents Journal Club

2007-2011 Director, Anxiety Disorders Clinic (PGY-III, Social Work, Interns, medical students)

2009 Lecture, “Introduction to Schizophrenia” (1st Year Biomedical Sciences Students)

 

Graduate Students

James Bazzetta, 1996-2000- Psychiatry Counseling- San Diego, CA

Tod Oliver, 1997- Sr. Development Specialist at NASA- Napa,CA

Anthony Rabin, 1997 –Clinical Psychologist -Napa, CA

Kristi Schearer, 1999 – Private Practice Psychology in New Mexico

Kassi Kronfeld, 2010 – Medical Student

Postgraduate Ph.D. Fellows

Julie Akiko Gladsjo, 1999-2001-Private Practice Dermatology

John Lucas, 1994 – Associate Professor of Psychology –Mayo Clinic

Jennifer Pike, 1998-2000 – Staff Psychiatrist – UCLA Medical Center

Michael Suminski, 1991-1994 – Private Practice- PA

Carol Rotko, 2009 –Time off to raising a family

 

Fellows Mentored

Margarita Alonzso MD, 1995-1997 – Private Practice- Downey, CA

Tahir Bhati MD, 1994-1996 – Assistant Clinical Professor, UCSD, CA

Jerry Bobo MD, 1994 – Private Practice- San Diego, CA

Shannen Chavez MD, 1998-2000 – Medical Director, UCSD Outpatient

Camilla Clark, 1994-1998 – Associate Clinical Professor –UCSD, CA

Douglas Dolnak DO, 1996-2001-Assist. Clinical Professor – UCSD, CA

Bruce Dow, 1992-1993 – Assist Clinical Professor-UCSD, CA

David Frakes MD, 1991 –Quintile Pacific Inc. –San Diego, CA

William Kinney MD, 1990-1992 –Private Practice – Chicago, IL

Jelena Kunovacs MD, 1997-2000 –Assoc. Clinical Professor-UCSD and Psychopharmacology Research, San Diego

John Lauriello MD, 1990-1991 –Chairman, Psychiatry University of Missouri, IL

Mauro Mendowicz MD, 1996-1999 – Private Practice

Gregory Panicia MD, 1993-1995 – Private Practice –San Diego, CA

Eric Raimo MD, 1996 – Private Practice – San Diego, CA

Howard Rubin MD, 1998-2000 –Private Practice- San Francisco, CA

Sherry Soefje MD, 1991-1993 –Assistant Clinical Professor, UCSD, CA

Leslie Tam MD, 1998-2000 –Private Practice

Peter Thompson MD, 1992-1994 – University of Texas, San Antonio, TX

Kendwth Chalakeeree MD, 1992-1994 –Private Practice

Olavo Pinto MD, 1999-2001 – Private Practice- San Diego, CA

Weigou Zhu MD, PhD , 2000-2002 –Associate Professor, USC, LA, CA

Marianne Dean MD, 2001 –Private Practice – MA

Kathy Ruiz-Mellott MD, 2004-2006 – Private Practice – San Mateo, CA

Vladimir Bokarius MD, 2006-2009 – Private Practice-LA County Judicial System,CA

Eugene Lee MD, 2009 –Homeless Project and Private Practice – NYC, NY

 

Mentored Undergraduates

James Bazzetta, 1994-1996

William Jay Evans, 1992-1994

Theresa Frevert, 1997- Psychologist, Project Manager ACM Global Central Laboratories

Diana Hu, 1997, Ophthalmologist in practice in Arizona

Rebecca McKinney, 1993-1994 – Research Associate at UCSD

Ray Mawhinney, 1998 – Musician in Los Angeles

Katia Delrahim-Howlett 2000-2004 – Deputy Director of the Underage Drinking Prevention Education Initiatives, Washington, DC

Rachel Maddux, 2000-2004 – Graduate Student in psychology in Uppsala, Sweden

Stefan Smertz, 2004-2005 – Graduate Student

Julie Schultz, 2005-2007 – Graduate Student UCLA

Katie Bresee, 2003-2005 – Biostatistics, Cedars Sinai

 

National Mentoring

1992-Current Co-Chair, New Investigators Program (NCDEU)

2000-2003 Research Mentor, APA Young Investigator Program

2005-2007 Research Mentor, APA Young Investigator Program

2006-2008 West Coast College Biological Psychiatry – Session on Career Development in Academic Psychiatry

2007 Research Mentor, ACNP Young Investigator Program

2009 Research Mentor, APA Young Investigator Program

2009 Research Mentor ACNP Young Investigator Program

2010 Research Mentor APA Young Investigator Program

2010 Invited Speaker NIMH Workshop for Early Stage Research Investigators

Lectureships, Seminars and Visiting Professorships

2013 Invited Speaker, Symposium – Psychoneuroimmunology, “Immunotherapeutic approaches for the treatment of depression” 11th World Congress of Biological Psychiatry, WFSBP, Kyoto, Japan

2013 Invited Speaker, Workshop 69 “ABPN and APA Perspectives on “Maintenance of Certification” APA 166th Annual Meeting, San Francisco, CA

2013 Invited Speaker, NCDEU NIA Program Panel Discussion, “Extramural Perspective” NCDEU 53rd Annual Meeting of the ACSP, Hollywood, FL

2013 Invited Speaker, NCDEU NIA Program “Getting a Job and Keeping It? NCDEU 53rd Annual Meeting of the ASCP, Hollywood, FL

2013 Invited Speaker, Panel Presentation: “How does Massage Work? Potential Mechanisms”, International Massage Therapy Research Conference, Massage Therapy Foundation, Boston, MA.

2013 Invited Speaker, Georgia Psychiatric Physicians Association (GPPA), “Maintenance of Certification Workshop” Atlanta, GA

2012 Invited Lecturer, “Residual Symptoms in Depression: Management and Prognosis”, Shanghai Mental Health Center, Shanghai, PR China

2012 Invited Speaker, Symposium “Psychoneuroimmunology in the Service of Personalized Medicine in Psychiatry”, World Psychiatric Association, Prague, Czech Republic

2012 Invited Speaker, Mental Health Lecture Series, “A Review of CAM Treatments for Mood and Anxiety Disorders, the Good, the Bad and the Ugly” School of Public Health, Emory University, Atlanta, GA

2012 Invited Speaker, Mood Disorders Panel, Rosalynn Carter Fellowships for Mental Health Journalism, The Carter Center, Atlanta, GA

2012 Invited Speaker, Symposium Internacional de Controversias en Psiquaitra: “Residual Symptoms In Depression: Management and Prognosis” Cancun, Mexico

2012 Invited Speaker, NCDEU Special Session: “Innovations in Life Long Learning for Psychiatrists: The Focus System” Phoenix, AZ

2012 Invited Speaker, APA Caucus Symposium: Integrative Psychiatry for Treatment of Mood & Anxiety Disorders Across the Life Cycle: CAM: Implications for Mood & Anxiety Disorders, Philadelphia, PA.

2012 Invited Speaker, Southern California Psychiatric Society, Psychopharmacology Update 23. “Bipolar Spectrum Disorders: Underdiagnosed? Over-diagnosed? Strategies for Treatment”

2011 Inaugural Speaker, Dorothy Chapman Fuqua Lecture Series, Skyland Trail, Atlanta, GA, “Off the Couch: Why Atlanta Can Transform Psychiatry in the 21st Century”

2011 Invited Speaker, Institute 7, American Academy of Child & Adolescent Psychiatry and Canadian Academy of Child and Adolescent Psychiatry, Toronto, Canada,”Complementary and Alternative Medicine”

2011 Invited Discussant, Workshop 26, American Academy of Child & Adolescent Psychiatry and Canadian Academy of Child and Adolescent Psychiatry, Toronto, Canada, “Grant Writing Workshop for Complementary and Integrative Medicine”

2011 Invited Speaker, 39th Anniversary Psychopharmacology Update, Las Vegas psychiatric Society Las Vegas, NV, “Major Depressive disorder: Where are We Going?”

2011 Keynote Speaker, 19th Annual Psychopharmacology Review Course: Current Clinical Practice, Tucson, AZ, “Diagnosis and Treatment of Bipolar Disorder”

2011 Grand Rounds, Georgia Health University, Augusta, GA, “Complementary and Alternative Therapies for Mood and Anxiety Disorders: The Good, the Bad, and the Ugly”

2011 Invited Speaker, Georgia Psychiatric Physicians Association (GPPA), Atlanta, GA, “Psychopharmacology for Depression and Mood Disorders: Tips for Success”

2011 Invited Discussant, Case Presentation, Georgia Psychiatric Physicians Association (GPPA), Atlanta, GA, “What Next? A case Presentation of Treatment Resistant Depression”

2010 Invited Discussant, WPA section on Immunology and Psychiatry and the Sekton Immunolgie in der Psychiatrie der Deutschen Gesellschaft fur Biologishe Psychiatrie, Munich, Germany, Round Table Discussion, “Immunology and Psychiatry”

2010 Invited Speaker, 18th European Congress of Psychiatry, Munich, Germany, Immune System and Inflammation in Schizophrenia Symposium, “Immune Sequelae in Schizophrenia: the Quest for Testable Hypotheses”

2010 Distinguished Speaker, 2010 Mental Health Research Day, Charles Drew University of Medicine and Science, Los Angeles, CA, “An Overview of Alternative Medicine Therapies in Psychiatry and a Brief Review of Psychoneuroimmunology”

2009 Invited Speaker Psychogenic Movement Disorders and Other Conversion Disorders 2nd International Conference, “Approaches for Psychogenic Movement Disorders and Somatiform Disorders”

2009 Invited Discussant ISCDD 2009 Annual Meeting, Las Vegas, NV, “The Evidence Based Methodology Initiative (EMI)”

2009 Invited Speaker University of Texas, Southwestern, Dallas, TX, Depression: the Path to Remission: 5th Annual Depression Update: “Complementary and Alternative Therapies for Mood and Anxiety Disorders”

2009 Invited Speaker Panel Discussion, Association for Academic Psychiatry, 2009 Annual Meeting, Washington DC, “The Evolution of CME: Opportunities for Academic Psychiatrist”

2009 Invited Speaker Workshop, Association for Academic Psychiatry, 2009 Annual Meeting, Washington, DC, “CME in Psychiatry: Moving Ahead in a Pharma-Lite World”

2009 Invited Speaker Presentation, American Psychiatric Association 1st APA Grand Rounds, (Middle East and North Africa), Dubai, “The Recognition, diagnosis and Management of Anxiety, Including Co-morbidity with Common Physical Illness (e.g., COPD, IBS, cancer)”

2009 Study Group Chair State-of-the-Art Updates for Psychiatrists, American Psychiatric Association 1st APA Grand Rounds, (Middle East and North Africa), Dubai, “Anxiety – new Research and Current Clinical Recommendations”

2008 Invited Speaker Presentation at College of Psychiatric & Neurologic Pharmacists (CPNP), Scottsdale, AZ: “Placebo Response Implications for Clinical Trials”

2008 Invited Lecturer Educational Symposium, XXVI Collegium Internationale Neuro-Psychopharmagologicum (CINP) Congress, Munich, Germany: “Future Drugs for the Treatment of Unipolar Depression”

2008 Invited Lecturer APA-SEP 1st Joint Meeting, Focus on Psychiatric Disorders, Barcelona, Spain: “Translating New Research Findings into the Treatment and Disability Prevention in Anxiety Disorders”

2008 Invited Lecturer APA-SEP 1st Joint Meeting, Focus on Psychiatric Disorders, Barcelona, Spain: “State of the Art for Anxiety Disorders Treatment”

2007 Invited Lecturer 12th Annual Psychopharmacology Update, Nevada Psychiatric Association, Las Vegas, NV: “New Strategies for Addressing Anxiety and Resistant Somatic Symptoms”

Publications

Published and Accepted Research Articles

1. Rapaport MH, Zisook S, Lyons L: “Factors influencing outpatient attrition.” Psychol Med,1988: 4(6):8-22

2. Breier A, Wolkowitz O, Rapaport MH, Paul SM, Pickar D: “Metabolic stress effects in normal volunteers and schizophrenic patients.” Psychopharmacol Bull, 1988:24(3):431-433

3. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky DS: “A blunted growth hormone response to peripheral infusion of human growth hormone releasing factor in patients with panic disorder.” Am J Psychiatry, 1989:146(1):92-95

4. Rapaport MH, Risch SC, Golshan S, Gillin JC: “Neuroendocrine effects of ovine corticotropin releasing hormone in panic disorder patients.” Biol Psychiatry, 1989:26(4): 344-348

5. Pato CN, Wolkowitz O, Rapaport MH, Schulz SC, Pickar D: “Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia.” Psychopharmacol Bull, 1989:25(2):263-266

6. McAllister CG, Rapaport MH, Pickar D, Podruchny TA, Christison G, Alphs LD, Paul SM: “Increased numbers of CD5 positive B lymphocytes in schizophrenic patients.” Arch Gen Psychiatry, 1989:46(10):890-894

7. Rapaport MH, McAllister CG, Pickar D, Nelson DL, Paul SM: “Elevated levels of soluble interleukin-2 receptors in schizophrenia.” Arch Gen Psychiatry, 1989:46(3):291-292

8. Litman RE, Hommer DW, Clem T, Rapaport MH, Pato CN, Pickar D: “Smooth pursuit eye movements in schizophrenia: Effects of neuroleptic treatment and caffeine.” Psychopharmacol Bull, 1989:25(3):473-478

9. McAllister CG, Rapaport MH, Pickar D, Paul SM: “Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients.” Arch Gen Psychiatry, 1989: 46(10):956-57

10. Lucas PB, Pickar D, Kelsoe J, Rapaport MH, Pato C, Hommer D: “Effects of the acute administration of caffeine in patients with schizophrenia.” Biol Psychiatry, 1990:28:35-40

11. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky DJ: “The effects of physostigmine infusion on patients with panic disorder.” Biol Psychiatry, 1991:29: 658-664

12. Rapaport MH, McAllister CG, Kirch D, Pickar D: “The effects of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness.” Biol Psychiatry, 1991:29: 715-717

13. Rapaport MH, Doran AR, Nelson DL, McAllister C, Maglioffi JR, Paul SM: “Acute haloperidol administration fails to alter serum soluble interleukin-2 receptors in healthy normal volunteers.” Biol Psychiatry, 1991:30:1063-1065

14. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH: “Clinical and biological response to Clozapine with schizophrenia: Crossover comparison with Fluphenazine.” Arch Gen Psychiatry, 1992:49:345-353

15. Rapaport MH, Wolkowitz O, Kelsoe JR, Pato C, Konicki EP, Pickar D: “The beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.” Neuropsychopharm, 1993:9(2):111-115

16. Rapaport MH, Tipp JE, Schuckit MA: “A comparison of ICD-10 and DSM-III-R criteria for substance abuse and dependence.” Am J Drug Alcohol Abuse, 1993:19(2), 143-151

17. Lauriello J, Kenney WM, Sutton L, Golshan S, Ruiz C, Kelsoe J, Rapaport MH, Gillin JC: “The cholinergic REM sleep induction test with pilocarpine in mildly depressed patients and normal controls.” Biol Psychiatry, 1993:33:33-39

18. Rapaport MH, Torrey EF, McAllister CG, Nelson DL, Pickar D, Paul SM: “Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins.” Eur Arch Psychiatry Clin Neurosci, 1993:243:7-10

19. Rapaport MH, McAllister CG, Kim YS, Han JH, Pickar D, Nelson DL, Kirch DG, Paul SM: “Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients.” Biol Psychiatry, 1994:35:767-771

20. Rapaport MH, Stein MB: “Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder.” Anxiety, 1994:1:22-25

21. Rapaport MH, Schmidt ME, Risinger R, Manji H: “The effects of prolonged lithium exposure on the immune system of normal control subjects: Serial serum soluble interleukin-2 receptor and anti-thyroid antibody measurements.” Biol Psychiatry, 1994:35:762-766

22. Judd LL, Rapaport MH, Paulus MP, Brown JL: “Subsyndromal symptomatic depression (SSD): A new mood disorder?” J Clin Psychiatry, 1994:55:18-28

23. Rapaport MH, Suminski M: “National Depression Screening Day: The San Diego experience.” H&CP, 1994:45:1042-1043

24. Rapaport MH, Lohr JB: “Serum soluble interleukin-2 receptors in neuroleptic naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia.” Acta Psychiatr Scand, 1994:90:311-315

25. Rapaport MH: “Immune parameters in euthymic bipolar patients.” J Affect Disord, 1994:32:149-156

26. Rapaport MH, Stein MB: “Serum interleukin-2 and soluble interleukin-2 receptor levels in generalized social phobia.” Anxiety, 1994:1:50-53

27. Rapaport MH, Thompson, P, Kelsoe J, Golshan S, Judd LL, Gillin JC: “Gender differences in outpatient research subjects with affective disorders: A comparison of descriptive variables.” J Clin Psychiatry, 1995:56(2):67-72

28. Rapaport MH, Frevert T, Babior S, Zisook S, Judd LL: “A comparison of demographic variables, symptom profiles and measurements of functioning in symptomatic volunteers and in outpatient clinical populations.” Psychopharmacol Bull, 1995:31(1):111-114

29. Gillin JC, Kenny WM, Lauriello J, Kelsoe JR, Rapaport M, Golshan S, Kenny W, Sutton L: “No antidepressant effect of biperiden, a muscarinic receptor (M1) antagonist, compared with placebo in depression.” J Psychiatr Res, 1995:58:99-105

30. Rapaport MH, Dow BM, Kelsoe JR, Golshan S, Gillin JC: “A comparison of mood ratings and co-morbid diagnoses in research subjects with major depression or stimulant dependence.” Eur Addict Res, 1996:2:24-28

31. Gillin J, Sohn JW, Stahl M, Lardon M, Kelsoe J, Rapaport MH, Ruiz C, Golshan S: “Ipsapirone, a 5HT1A agonist, suppresses REM sleep equally in unmedicated depressed patients and normal controls.” Neuropsychopharm, 1996:15 (2):109-115

32. Kelsoe JR, Remick RA, Sadovnick AD, Kristbjarnarson H, Flodman P, Spence MA, Morison M, Mroczkowski-Parker Z, Bergesch P, Rapaport MH, Mirow AL, Blakely RD, Helgason T, Gillin JC, Egeland JA: “A genetic linkage study of bipolar disorder and the serotonin transporter.” Am J Med Genet, 1996:67:215-217

33. Rapaport MH, Frevert T, Babior S, Seymour S, Zisook S, Kelsoe J, Judd LL: “A comparison of descriptive variables for symptomatic volunteers and clinical patients with anxiety disorders.” Anxiety, 1996:2(3):117-122

34. Rapaport MH, Bazzetta J, McAdams LA, Patterson T, Jeste DV: “Validation of the scale of functioning in older outpatients with schizophrenia.” Am J Geriatr Psychiatry, 1996:4(3): 218-228

35. Rapaport MH, Zisook S, Frevert T, Seymour S, Kelsoe JR, Judd LL: “A comparison of descriptive variables for clinical patients and symptomatic volunteers with depressive disorders.” J Clin Psychopharmacol, 1996:16(3):242-246

36. Rapaport MH, Coccaro E, Sheline Y, Perse T, Holland P, Fabre L: “A comparison of fluvoxamine and fluoxetine in the treatment of major depression.” J Clin Psychopharmacol, 1996:16(5):373-378

37. Judd LL, Paulus MP, Wells KB, Rapaport MH: “Socio- economic burden of subsyndromal depressive symptoms and major depression in a sample of the general population.” Am J Psychiatry, 1996:153: 1411-1417

38. Kelsoe JR, Sadovnick AD, Kristbjarnarson H, Bergesch P, Mroczkowski-Parker Z, Drennan M, Rapaport MH, Flodman P, Spence MA, Remick RA: “A possible locus for bipolar disorder near the dopamine transporter on chromosome 5.” Am J Med Genet, 1996:67:533-540

39. Alonso M, Val E, Rapaport MH: “An open label study of SSRI treatment in depressed Hispanic and non-Hispanic women.” Letter to Editor, J Clin Psychiatry, 1997:58:31

40. Gillin JC, Rapaport MH, Erman MK, Winokur A, Albala BJ: “A comparison of Nefazodane and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, eight week clinical trial.” J Clin Psychiatry, 1997:58(5):185-192

41. Lachman HM, Kelsoe JR, Remick RA, Sadovnick AD, Rapaport MH, Lin M, Pazur BA, Roe AA, Saito T, Papolos DF: “Linkage studies support a possible locus for bipolar disorder in the velo-cardio-facial syndrome region on chromosome 22.” Am J Med Genet, 1997:74:121-128

42. Noyes R Jr, Moroz G, Davidson JRT, Liebowitz MR, Davidson A, Siegel J, Bell J, Cain J, Curlik SM, Kent T, Lydiard B, Mallinger A, Pollack M, Rapaport MH, Rasmussen S, Reimherr F, Schweizer E, Uhlenhuth EH: “Moclobemide in social phobia: a controlled dose-response trial.” J Clin Psychopharmacol, 1997:17(4):247-254

43. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM: “CSF interleukin-2 levels in medicated schizophrenic subjects.” Schizophr Res, 1997:25:123-129

44. Rapaport MH, Caliguiri MP, Lohr, JB: “An association between increased serum soluble interleukin-2 receptors and a disturbance in motor muscle force in schizophrenic patients.” Prog Neuropsychopharmacol Biol Psychiatry, 1997:21(5):817-827

45. Lachman HM, Kelsoe JR, Remick RA, Sadovnick AD, Rapaport MH, Lin M, Pazur BA, Roe AA, Saito T, Papolos DF: “Linkage studies suggest a possible locus for bipolar disorder in the velo-cardio-facial syndrome region on chromosome 22.” Am J Med Genet, 1997:74:121-128

46. Rapaport MH: “Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers.” Biol Psychiatry, 1998:43: 458-463

47. Gladsjo JA, Rapaport MH, McKinney R, Lucas J, Rabin A, Oliver T, Davis J, Auerbach M, Judd LL: “A neuropsychological study of panic disorder: negative findings.” J Affect Disord, 1998: 49(2):123-131

48. Rapaport MH and Judd LL: “Minor depressive disorder and subsyndromal depressive symptoms: Functional impairment and response to treatment.” J Affect Disord, 1998:48(2-3):227-232

49. Mendlowicz MV, Rapaport MH, Mecler K, Shahrokh G, de Moraes TM: “A case-control study on the socio-demographic characteristics of 53 neonaticidal mothers.” Int J Law Psychiatry, 1998: 21(2):209-219

50. Rapaport, MH, Wolkow RM, Clary CM: “Methodologies and outcomes from the sertraline multicenter flexible dose trials.” Psychopharmacol Bull, 1998:34(12):183-189

51. Bhatti T, Seifritz E, Moore P, Clark C, Golshan S, Stahl S, Rapaport MH, Kelsoe J, Gillin JC: “Effects of a tryptophan-free amino acid drink challenge on normal human sleep EEG and mood.” Biol Psychiatry, 1998:43(1):52-59

52. Moore P, Gillin, JC, Bhatti T, Seifritz E, Clark C, Stahl S, Rapaport MH, Kelsoe J: “Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors.” Arch Gen Psychiatry, 1998:55(6):534-539

53. Seifritz E, Gillin JC, Rapaport MH, Kelsoe JR, Bhatti T, Stahl SM: “Sleep electroencephalographic response to muscarinic and serotonin receptor probes in patients with major depression electroencephalographic response to muscarinic and serotonin receptor probes in patients with major depression and in normal controls.” Biol Psychiatry, 1998:44:21-33

54. Mendlowicz MV, Rapaport MH, Thompson P, Kelsoe JR, Golshan S, Judd LL, Gillin JC: “A comparison of descriptive characteristics of male outpatients and inpatients with affective disorders.” Int Clin Psychopharmacol, 1998:13(6):245-252

55. Mendowicz MV, Jean-Louis G, Gekker M, Rapaport MH: “Neonaticide in the city of Rio de Janeiro: forensic and psycholegal perspectives.” J Forensic Sci, 1998:741-745

56. Rapaport MH, Guylai L, Whybrow P: “Immune parameters in rapid cycling bipolar patients before and after lithium treatment.” J Psychiatr Res, 1999:33:335-340

57. Rapaport MH, McAllister CG: “The genetics of obsessive-compulsive disorder: An immunologic perspective.” CNS Spectrums, 1999:4(6):71-77

58. Saito T, Papolos DF, Chernak D, Rapaport MH, Kelsoe JR, Lachman HM: “Analysis of GNAZ gene polymorphism in bipolar affective disorder.” Am J Med Genet, 1999:88(4):324-328

59. Rubin HC, Rapaport MH, Levine B, Gladsjo JK, Rabin A, Auerbach M, Judd LL, Kaplan R: “Quality of well being in panic disorder: The assessment of psychiatric and general disability.” J Affect Disord, 2000:57(1-3):217-221

60. Mendlowicz MV, Rapaport MH, Jean-Louis G, Filho JF, Gekker M, de Moraes TM: “Mothers murdering their newborns in the hospital.” Gen Hosp Psychiatry, 2000:22(1):53-55

61. Jean-Louis G, Mendolowicz MV, Gillin JC, Rapaport MH, Kelsoe JR, Zizi F, Landolt H-P, von Gizycki H: “Sleep estimation from wrist activity in patients with major depression”. Physiol Behav, 2000:70(1-2):49-53

62. Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C: “Is placebo response the same as drug response in panic disorder?” Am J Psychiatry, 2000:57(6): 1014-1015

63. Clark C, Dupont R, Golshan S, Gillin JC, Rapaport MH, Kelsoe JR: “Preliminary evidence of an association between increased REM density and poor antidepressant response to partial sleep deprivation.” J Affect Disord, 2000:59(1):77-83

64. Mendlowicz MV, Jean-Louis G, Gillin JC, Akiskal HS, Furlanetto LM, Rapaport MH, Kelsoe JR: “Sociodemographic predictors of temperament and character.” J Psychiatr Res, 2000:34(3):221-226

65. Kornberg JR, Brown JL, Sadovnik AD, Remick RA, Keck PE Jr. McElroy SL, Rapaport MH, Thompson PM, Kaul JB, Vrabel CM, Schommer SC, Wilson T, Pizzuco D, Jameson S, Schibuk L, Kelsoe JR: “Evaluating the parent-of-origin effect in bipolar affective disorder: is a more penetrant subtype transmitted paternally?” J Affect Disord, 2000:59(3):183-192

66. Moore P, Landolt HP, Seifritz E, Clark C, Bhatti T, Kelsoe J, Rapaport M, Gillin JC: “Clinical and physiological consequences of rapid tryptophan depletion.” Neuropsychopharm, 2000:23(6):601- 622
67. Pollack MW, Rapaport MH, Clary CM, Mardekian J, Wolkow R: “Sertraline treatment of panic disorder: Response in patients at risk for poor outcome.” J Clin Psychiatry, 2000:61: 922-927

68. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET for the Lamictal 614 Study Group: “A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid cycling bipolar disorder.” J Clin Psychiatry, 2000:61: 841-850

69. Kelsoe JR, Spence MA, Loetscher E, Foguet M, Sadovnick AD, Remick RA, Flodman P, Khristich J, Mroczkowski-Parker Z, Brown JL, Masser D, Ungerfeider S, Rapaport MH, Wishart WL, Luebbert H: “A genome survey indicates a susceptibility locus for bipolar disorder on chromosome 22.” Proc Nat’l Acad Sci USA, 2001:98:585-590

70. Thorsteinsson HS, Gillin, JC, Patten,CA, Golshan S, Sutton LD, Drummond S, Clark, CP, Kelsoe J, Rapaport MH. “The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression.” Neuropsychopharm, 2001:24(4): 350-358

71. Rapaport MH, Pollack MH, Clary CM, Mardekian J, Wolkow R: “Panic disorder and response to sertraline: The effect of previous treatment with benzodiazepines.” J Clin Psychopharmacol, 2001: 21:104-107

72. Paulus MP, Rapaport MH, Braff DL: “Trait contributions of complex dysregulated behavioral organization in schizophrenia patients.” Biol Psychiatry, 2001:49(1):71-77

73. Landolt H-P, Raimo EB, Schnierow BJ, Kelsoe JR, Rapaport MH, Gillin JC: “Sleep and sleep electroencephalogram in depressed patients treated with phenelzine.” Archives of General Psychiatry, 2001:58: 268-276

74. Gladsjo JA, Rapaport MH, McKinney R, Auerbach M, Hahn T, Rabin A, Oliver T, Hazen A, Judd LL: “Absence of neuropsychological deficits in patients on long-term therapy with alprazolam-XR for panic disorder.” J Clin Psychopharmacol, 2001:21: 131-138

75. Patten CA, Gillin JC, Golshan S, Wolter TD, Rapaport M, Kelsoe J: “Relationship of mood disturbance to cigarette smoking status among 252 patients with a current mood disorder.” J Clin Psychiatry, 2001:62(5): 319-324

76. Rapaport MH, Manji JK: “The effects of lithium on ex vivo cytokine production.” Biol Psychiatry, 2001:50:217-224

77. Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, Rapaport MH, Kaplan RM, Brown SI: “Depression, visual acuity, co-morbidity and disability associated with age-related macular degeneration.” American Academy of Ophthalmology, 2001:108(10) 1893-1900

78. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M: “Sertraline treatment of panic disorder: Results of a long term study.” Acta Psychiatry Scand, 2001:104: 289-298

79. Moore P, Seifritz E, Schlosser A, Greenfield D, Stahl S, Rapaport M, Kelsoe J: “Rapid tryptophan depletion plus a serotonin 1A agonist: Competing effects on sleep in healthy men.” Neuropsychopharm, 2001:25(S5):S40-S44

80. Moore PJ, Gillin JC, Rapaport MH, Kelsoe J: Letter to Editor re: Response to FG Miller and DL Rosenstein letter: “Does rapid tryptophan depletion induce depressive relapse?” Neuropsychopharm, 2001:25(4):614-615

81. Gillin JC, Smith-Vaniz A, Schnierow B, Rapaport MH, Kelsoe J, Raimo E, Marler MR, Goyette LM, Stein MB, Zisook S: “An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related post traumatic stress disorder.” J Clin Psychiatry, 2001:62(10):789-796

82. Rapaport MH, Endicott J, Clary CM: “Posttraumatic stress disorder and quality of life: Results across 64 weeks of sertraline treatment.” J Clin Psychiatry, 2002:63(1): 59-65

83. Rapaport MH, Judd LL, Schettler PJ, Yonkers KA, Thase ME, Kupfer DJ, Frank E, Plewes J, Tollefson GD, Rush AJ: “A descriptive analysis of minor depression.” Am J Psychiatry, 2002: 159(4):637-643

84. Mendlowicz MV, Rapaport MH, Fontenelle L, Jean-Louis G, De Moraes TM: “Amnesia and neonaticide: A few questions raised by a systematic investigation of 16 cases of neonaticide.” Am J Psychiatry, 2002:159(3): 498-499
85. Pollack MH, Rapaport MH, Fayyad R, Otto MW, Clary CM: “Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder.” J Psychiatr Res, 2002: 36:229-236

86. Evans L, Golshan S, Kelsoe J, Rapaport MH, Resovsky K, Sutton L, Gillin JC: “Effects of rapid tryptophan depletion on sleepelectroencephalogram and mood in subjects with partially remitted depression on bupropion.” Neuropsychopharmacol, 2002:27(6):1016-1026

87. Wang XF, Wang D, Zhu W. Delrahim KK, Dolnak D, Rapaport MH: “Studies characterizing 60kDa antibodies in subjects with schizophrenia.” Biol Psych, 2003; 53(5):361-75

88. Landholt HP, Kelsoe JR, Rapaport MH, Gillin JC: “Rapid tryptophan depletion reverses phenelzine-induced suppression of REM sleep.” J Sleep Res, 2003;12(1):13-8

89. Pyne JM, Sieber WJ, David K, Kaplan RM, Rapaport MH, Williams DK: “Use of the quality of well-being self-administered version (QWB-SA) in assessing health-related quality of life in depressed patients.” J Aff Disord, 2003; 76: 237-247

90. Rapaport MH, Schneider LS, Dunner DL, Truman M, Pitts CD: “Efficacy of controlled-release paroxetine in the treatment of late-life depression.” J Clin Psychiatry, 2003;64:9: 1065-1074

91. Caligiuri MP, Gentili V, Eberson S, Kelsoe J, Rapaport MH, Gillin JC: “A quantitative neuromotor predictor of antidepressant non-response in patients with major depression.” J Affect Disord, 2003 Nov;77(2):135-41

92. Van Kammen DP, Chengappa KNR, Shiwach R, Lesem M, Wang D, Topamax Psychiatry Phase II Study Group: “A placebo-controlled study of topiramate in acute mania (bipolar I disorder): Trials and tribulations of conducting an acute mania study.” 2003

93. Meltzer HY, Alphs L. Green Al, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S, International Suicide Prevention Trial Study Group: “Erratum in: Arch Gen Psych 2003: July60(7):735”, Arch Gen Psych 2003: Jan 6- (1):82-91.

94. 125. Potkin SG, Alphs L, Hsu C, Krishnan KR, Anand R, Young FK, Meltzer H, Green A, InterSePT Study Group: “Predicting Suicidal Risk in Schizophrenia and Schizoaffective Patients in a Prospective 2-Year Trial” Biol Psychiatry 2003: Aug 15:54(4):444-52.

95. Rapaport MH, Bose A, Zheng H: “Escitalopram continuation treatment prevents relapse of depressive episodes.” J Clin Psychiatry, 2004;65;(1):44-49

96. Judd LL, Rapaport MH, Yonkers KA, Rush AJ, Frank E, Thase ME, Kupfer DJ, Plewes JM, Schettler PJ, Tollefson G: “Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.” Am J Psychiatry; 2004;161:1864-1871

97. Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr P, Rupnow M: “Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores.” Schizophrenia Research, 2004;71:155-165

98. Haynes PL, McQuaid JR, Kelsoe J, Rapaport MH, Gillin JC: “Affective state and EEG sleep profile in response to rapid tryptophan depletion in recently recovered nonmedicated depressed individuals.” J Affective Disorder, 2004;83:253-262

99. Mendlowicz MV, Akiskal HS, Kelsoe JR, Rapaport MH, Jean-Louis G, Gillin JC: “Temperament in the clinical differentiation of depressed bipolar and unipolar major depressive patients.” J Affect Disord, 2005;84(2-3):219-23

100. Akiskal HS, Mendlowicz MV, Jean-Louis G, Rapaport MH, Kelsoe JR, Gillin JC, Smith TL: “TEMPS-A: Validation of a short version of a self-rated instrument designed to measure variations in temperament.” J Affect Disord, 2005;85(1-2):45-52

101. Khan A, Kolts RL, Rapaport MH, Krishnan KR, Brodhead AE, Brown WA: “Magnitude of placebo response and drug-placebo differences across psychiatric disorders.” Psychological Medicine, 2005;35(5): 743-749

102. Rapaport MH, Clary C, Endicott J, Fayyad R: “Quality of life impairment in depressive and anxiety disorders.” Am J Psychiatry, 2005;162:6:1171-8

103. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D: “Celecoxib augmentation of continuously ill patients with schizophrenia.” Biol Psych, 2005;57:1594-1596

104. Bresee CJ, Delrahim KK, Maddux RE, Dolnak D, Ahmadpour O, Rapaport MH: “The effects of celecoxib on cytokine levels in schizophrenia.” Int J Neuropsychopharm, 2005;8:1-6

105. Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis S, Howland R, Kling MA, Rittberg BR, Burke WJ, Rapaport MH, Zajecka J, Neirenberg AA, Husain MM, Ginsberg D, Cooke RG: “Vagus nerve stimulation (VNS) for treatment-resistant depression: A randomized, controlled acute phase trial.” Biol Psych, 2005;58:347-354

106. Rapaport MH, Gharabawi GM, Canuso C, Mahmoud RA, Nemeroff C, Keller M, Bossie C, Turkoz R. Loescher A, Bouhours P, Dunbar F, Lasser RA: “Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation.” Neuropsychopharm, 2006;31(11):2505-13

107. Shelton RC, Haman KL, Rapaport MH, Kiev A, Smith WT, Hirschfeld RM, Lydiard B, Zajecka JM, Dunner DL: “A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depression.” J Clin Psychiatry, 2006:67:1674-1681

106. Rapaport MH, Skarky SB, Katzelnick DJ, DeWester JN, Harper JM, McCrary KE: “Time to response in generalized anxiety disorder in a naturalistic setting: Combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone.” Psychiatry, 2006:3(12)50-59

107. Howland RH, Nierenberg AA, Schettler PJ, Rapaport MH, Mischoulon D, Schneider T, Fasiczka A Kelrahiem K, Maddux R, Lightfoot M, Nierenberg, AA: “Clinical features and functioning of patients with minor depression.” Psychother Psychosom, 2008;77:384-389

108. Gyulai L, Bauer MS, Marangell LB, Dennehy EB, Thase ME, Otto MW, Zhang H, Wisniewski SR, Miklowitz DJ, Rapaport MH, Baldassano CF, Sachs GS: “Correlates of functioning in bipolar disorder.” Psychopharmacol Bull, 2008; 41(4:1)51-53

109. Binesh N, Cohen RM, Moser FG, Maya MM, Pressman BD, Rapaport MH: “Does massage
therapy affect brain metabolites?” The Internet Journal of Alternative Medicine, ISSN1540-2584 2008:Volume 5, Number 2

110. Marangell LB, Dennehy EB, Miyahara S, Wisniewski SR, Bauer MS, Rapaport MH, Allen MH, The functional impact of subsyndromal depressive symptoms in bipolar disorders: Data from STEP-BD.” J Affect Disord, 2009:114(1-3):58-67

111. Rapaport MH, Lydiard RB, Pitts CD, Schaefer D, Bartolic EI, Lyengar M, Carfagno M, Lipschitz A: “Low doses of controlled-release paroxetine in the treatment of late-life depression: A randomized, placebo-controlled trial.” J. Clin Psychiatry, 2009;70(1)46-57

112. Bresee CJ, Rapaport MH: “Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia.” Int J Neuropsychopharm. 2009:12,861-865.

113. Robinson Jr. D, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, Navarra Hsu B Revicki D, Cella D, Rapaport MH, Renahan K, Ress R, Wallace D, Weisman M: “The Impact of Systemic Lupus Erthematosus on Health, Family, and Work; the Patient Perspective” Arthritis Care and Research, 2010:62(2): 266-273

114. Nierenberg AA, Rapaport MH, Schettler PH, Howland RH, Smith JA, Edwards D, Schneider T, Mischoulon D: “Deficits in Psychological Well-Being and Quality of Life in Minor Depression: Implications for DSM-V.” CNS Neuroscience &Ther, 2010:16:208-216

115. Rapaport MH, Schettler PJ, Bresee CJ: “A Preliminary Study of the Effects of a Single Session of Swedish Massage on Hypothalamic-Pituitary-Adrenal and Immune Function in Normal Individuals” JACM, 2010:16(10):1-10

116. Rapaport MH, Bresee C: “Serial Mitogen-Stimulated Cytokine Production from Continously Ill Patients with Schizophrenia.” Neuropsychopharm. 2010:35,428-434

117. Vilhauer JS, Young S, Kealoha C, Borrmann J, IsHak WW, Rapaport MH: “Treating Major Depression by Creating Positive Expectations for the Future: a Pilot Study for the Effectives of Future Directed Therapy (FDT) on symptom severity and quality of life” CNS Neuroscience & Therapeutics 2011:00:1-8

118. Yager J, Silverman J, Rapaport MH: “Adapting to Decreased Industry Support of CME: Lifelong Education in an “Industry-Lite” World” Academic Psychiatry, 2011:35(2)101-105

119. Rapaport, MH Neirenberg A, Howland R, Mischoulon D, Darding C. Schettler PJ: “The Treatment of Minor Depression with St. John’s Wort or Citalpram: Failure to Show Benefit Over Placebo” Journal of Psychiatric Research 2011 Jul;45(7):931-41.

120. Bokarius A, Ha K, Poland R, Bokarius V, Rapaport MH, Ishak WW: “Attitude Toward Humor in Patients Experiencing Depressive Symptoms” Innovations in Clinical Neuroscience 2011:8(9)14-17.

121. Turner N, Macfadden W, Anand R, Khanna S, Rapaport MH, Haskins JT, Turkoz I, Alphs L: “Use of a Relapse Monitoring Board: An Independent Assessment for Determining Relapse in Clinical Trials for Bipolar Disorder” Innovations in Clinical Neuroscience 2011: 8(10)19-24.

122. Wisner KL, Conley RR, Taylor S, Kosten T, Rapaport MH, Brown L: “Influence of IRB Reviews on Neuroscience Research” IRB: Ethics & Human Research 2011:Sep-Oct 33(5): 14-20.

123. Fan A, Berg A, Bresee C, Glassman LH, Rapaport MH: “Allopurinol Augmentation in the Outpatient Treatment of Bipolar Mania: a Double-blind, Randomized, Placebo-controlled Pilot Study” Bipolar Disorders. 2012: 13: 206-210.

124. Ishak WW, Balayan K, Bresee C, Greenberg JM, Fakhry H, Christensen S, and Rapaport MH: “A Descriptive Analysis of Quality of Life Using Patient-Reported Measures in Major Depressive Disorder in a Naturalistic Outpatient Setting,” Quality of Life Research Journal” Online, April 29, 2012.

125. Gertsik L. Poland RE, Bresee C, Rapaport MH: “Omega-3 Fatty Acid Augmentation of Citalopram Treatment of Patients with Major Depressive Disorder” J.Clin Psychopharm 2012: Feb 32(1)61-4.

126. Targum SD, Little JA, Lopez E, Demartinis N, Rapaport MH, Ereshefsky L: “Application of external review for subject selection in a schizophrenia trial” J. Clin Psychopharm 2012:Apr 32 (2):825-6.

127. Rapaport MH, Schettler PJ, Bresee C: “A Preliminary Study of the Effects of Repeated Massage on Hypothalamic-Pituitary-Adrenal and Immune Function in Normal Individuals: The Effect of Dosage” JACM 2012:Vol 18 (8): 1-9.

128. Papakostas GI, Vitolo OV, Waguih WI, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D et al: “A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Majory Depressive Disorder”, Journal of Clinical Psychiatry 2012: Vol 73 (12) 1541-1547.

129. Pato MT., Sobell JL, Medeiros H, Abbott C, Skar B, Buckley PF, Bromet EJ, Escamila MA, Fanous AY, Lehrer DS, Macciardi F, Malaspoina D, McCarroll SA, Marder SR, Moran J, Morley CP, Nicolini H, Perkins DO, Purcell SM, Rapaport MH, Sklar P, Smoller JW, Knowles JA, Genomic Psychiatry Consortium, Pato CN. “The Genomic Psychiatry Cohort: Partners in Discovery” Am J Med Genet B Neuropsychiatr Genet, 2013, Jun, 162(4): 306-12.

130. Garlow SJ, Kinkead B, Thase M, Judd LL, Rush J, Yonkers K, Kupfer DJ, Frank E, Schettler PJ, Rapaport MH: “Fluoxetine Increases Suicide Ideation Less than Placebo During Treatment of Adults with Minor Depressive Disorder” Journal of Psychiatric Research, 2013. (47) 1199-1203.

 

In Press

Miller BJ, Culpepper N, Rapaport MH: “C-Reactive Protein Levels in Schizophrenia: A Review and MetaAnalysis”, Clinical Schziophrenia & Related Psychoses, In Press. DOI: 10.3371/CSPP.MICU.020813.

Rakofsky JJ, Schettler PJ, Kinkead BL, Frank E, Judd LL, Kupfer DJ, Rush JA, Thase ME, Yonkers KA, Rapaport MH: “The Prevalence and Severity of Depressive Symptoms along the Spectrum of Unipolar Depressive Disorders: A Post-hoc Analysis”, Journal of Clinical Psychiatry, 2013. In press

Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell JL, GPCC, Knowles JA, Bierut LJ, Pato MT: “Comorbidity of Severe Psychotic Disorders with Measures of Substance Abuse,” JAMA, 2013 In press.

 

Submitted

Mischoulon D, Nierenberg A, Schettler PJ, Kinkead B, Fehling K, Martinson M, Rapaport MH. “A Doubhle Blind, Randomized Controlled Clinical Trial Comparing Eicosapentaoenoic Acid (EPA) versus Docosahexaenoic Acid (DHA) for Major Depressive Disorder” JAMA, 2013.

 

Review Articles

1. Judd LL, Rapaport MH: “Risperidone, a new antipsychotic medication for the treatment of schizophrenia.” Innovations & Research, 1994:3(1):1-15

2. Judd LL, Rapaport MH: “Effect of pharmacotherapy on suicidal ideation and behavior.”

3. Judd LL, Rapaport MH: “Economics of depression and cost benefit comparisons of selective serotonin re-uptake inhibitor and tricyclic antidepressants.” Depression, 1994-1995:2:169-172

4. Rapaport MH, Paniccia G, Judd LL: Advances in the epidemiology and therapy of social phobia: directions for the nineties – a review of social phobia.” Psychopharmacol Bull, 1995:31(1):125-129.

5. Paniccia GS, Rapaport MH: Serotonin receptors, social phobia and panic disorder.” International Review of Psychiatry, 1995:7:121-130.

6. Rapaport MH, Judd LL: Review of the diagnosis and treatment of depression for the non-mental health professional.” Depression, 1995:3 108-120

7. Rapaport MH, Cantor JJ: “The treatment of panic disorder in a managed care environment.” J Clin Psychiatry, 1997:58(2):51-55

8. Rapaport MH: “The treatment of minor depression and depressive symptoms.” Journal of Depressive Disorders Index & Reviews, 1997:2(4):8-9

9. Rapaport MH, Barrett C: “Panic Disorder.” Current Psychiatry Reports, 2001:3:295-301

10. Rapaport MH: “Prevalence, recognition, and treatment of comorbid depression and anxiety.” J Clin Psychiatry, 2001:64(s24):6-10

11. Delrahim KK, Rapaport MH: “An abbreviated review of immune abnormalities in schizophrenia.” CNS Spectrums 2001:6(5): 392-397

12. Delrahim BA, Maddux R, Rapaport MH: “Long-term antidepressant treatment.” Psychopharmacol Bull 2002; 36(S3): 26-38

13. Rapaport MH, Maddux RE: “Challenges in the development of clinical trials for major depressive disorder: Lessons learned from trials in minor depression.” Dialogue Clin Neurosci, 2002;4: 402-407

14. Rapaport MH, Hales DJ: “Relapse prevention in bipolar disorder: A Focus on Bipolar Depression.” Focus, 2003;1:1:15-31

15. Maddux RE, “Delrahim KK, Rapaport MH: “Quality of life in geriatric patients with mood and anxiety disorders.” CNS Spectr, 2004; 2(3):35-47

16. IsHak WW, Rapaport MH, Gotto JG: “The effective of atypical antipsychotic medications in depressive disorders.” Current Psychiatry Reports, 2004:6422-424

17. IsHak WW, Rapaport MH, Gotto JG: Emerging treatment options in treatment resistant depression and anxiety disorders.” Spectr, 2004;9(12)14:25-32

18. Schultz J, Gotto JG, Rapaport MH: “The diagnosis and treatment of generalized anxiety disorder.” Primary Psychiatry, 2005;12,11:58-67

19. Rowe S, Rapaport MH: “Classification and treatment of sub-threshold depression.” Current Opinion in Psychiatry, 2006;19.9-13

20. Rapaport MH: “Dietary restrictions and drug interactions with monoamine oxidase inhibitors: The state of the art.” J.Clin Psychiatry, 2007;68: (suppl 8):42-46

21. IsHak WW, Davis M, Jeffrey J, Balayan K, Pechnick RN, Bagot K, Rapaport MH: “The Role of Dopamingeric Agents in Improving Quality of Life in Major Depressive Disorder” Mood Disorders, Current Psychiatry Reports, 2009:11:503-508

22. IsHak, WW; Greenberg, M; Balayan, K; Kapitanski, N; Jeffrey, J; Fathy, H; Fakhry, Hala; Rapaport, MH: “Quality of Life: The Ultimate Outcome Measure of Interventions in Major Depressive Disorder” Harvard Review of Psychiatry, 2011:19:229-239

23. IsHak WW, Ha K, Kapitanski N, Bagot K, Fathy H, Swanson B, Vilhauer J, Balayan K, Bolotaulo NI, Rapaport MH: “The Impact of Psychotherapy, Pharmacotherapy, and their Combination on Quality of Life in Depression” Harvard Review of Psychiatry, 2011.

24. Miller B, Culpepper N, Rapaport MH, Buckley, P: “Prenatal Inflammation and Neurodevelopment in Schizophrenia” Progress in Neuro-Psychopharmacol & Biol Psych. Special Issue: 2013: Vol 42:92-100.

 

Symposium Contributions

1. Rapaport MH: “Immunological findings in schizophrenia.” In: Exerpta Medica VIII World Congress of Psychiatry, 1991, Elsevier

2. Rapaport MH, Judd LL: “New subtypes of depression: implications for research.” In: Excerpta Medica IX World Congress of Psychiatry, 1994: Elsevier Press

3. Judd LL, Paulus M, Akiskal H, Rapaport MH, Kunovac JL, Robertson, P: “The role of subsyndromal depressive symptoms in unipolar major depression.” Bibliotheca Psychiatrica, 1997:167:6-10

4. Rapaport MH and Davidson J: “Pharmacological studies in panic disorder: The efficacy of new pharmacological treatments for panic disorder: evaluating the trials.” Psychopharmacol Bull, 1998:34(2):167-168

 

Book Chapters

1. Shiromani P, Rapaport MH, Gillin JC: “The neurobiology of sleep: basic concepts and clinical implications.” In: Hales and France (eds), Amer Psych Assoc Annual Update, 1987:(Vol VI). Wash., DC

2. Wolkowitz OM, Rapaport MH, Pickar D, Benzodiazepine augmentation of neuroleptics, “ In Schultz and Angrist(eds). Augmentation Strategies for Treatment Refractory Schizophrenic Patients, Washington, DC., 1990: Amer Psych Press

3. Rapaport MH, McAllister CG: “Neuroimmunological factor in schizophrenia.” In: Gorman and Kertzner (eds), Psychoimmunology Updates, Amer Psych Press, 1991:Ch 3:31-54

4. McAllister CG, Rapaport MH, Paul SM: “The role of autoimmunity in schizophrenia.” In: Schultz and Tamminga (eds), Schizophrenia, 1991, Raven Press

5. Judd LL, Paulus M, Akiskal HS, Rapaport MH, Kunovac JL: “The role of subsyndromal depressive symptoms in unipolar major depression.” In: Basic and Clinical Science of Mental and Addictive Disorders, (eds,, Judd LL, Saletu B, and Filip V) Basel, Switzerland, Karger Press, 1997:67:6-10

6. Rapaport MH, Caliguiri M, Lohr JB, Dolnak D, Chavez S, Kulesh C, Hahn T: “A preliminary analysis investigating immune activation in schizophrenia.” Muller N (ed), Psychiatry, Psychoimmunology, and Viruses, 1999:101-114

7. Rapaport MH, Muller N: “Immunological states associated with schizophrenia.” In: Ader, Felten, Cohen (eds) Psychoneuroimmunology, Third Edition, 2001:Vol.2, pp.373-382

8. Barrett C, Rapaport MH: “Anxiety Disorders.” Psychiatric Clinics of North America.” 2001:8: 181-208

9. Maddux RE, Rapaport MH: “Anxiolytic Drugs.” In: Tasman A, Kay J, Lieberman J (eds), Psychiatry-Second Edition, 2003; Vol.11:2033-2049, Wiley & Sons

10. Maddux RE, Rapaport MH: “Psychopharmacology and psychotherapy of subsyndromal depressions.” In: Alpert, Fava (eds) Handbook of Chronic Depression: Diagnoses and Therapeutic Management, 2004;183-206 Marcel Dekker.

11. Koury MA, Rapaport MH: “Quality of life impairment in anxiety disorders.” M.S.Ritsner and A.G. Awad (eds), Mood and Anxiety Disorders, Springer 2007;275-291

12. Rapaport MH, Edwards DM, Hale KL, Maddux RE: “Anxiolytic Drugs.” Chapter 104, Psychiatry Third Edition, 2008; Vol2:2223-2253

13. Bresee CJ, Gotto J, Rapaport MH: Treatment of Depression.” In: Schatzberg AF, Nemeroff CB (eds), The American College of Neuropsycho Pharmacology Textbook of Psychopharmacology, Fourth Edition, APPI, 2009; 1081-1111

14. Shaywitz J, Rapaport MH: “Treatment of Depression” In: Schatzberg AF, Nemeroff CB (eds), The American College Neuropsychopharmacology Textbook of Psychopharmacology, Fifth Edition,
APPI.

15. Edwards E, Mischoulon D, Rapaport MH, Stussman B, Weber W: “Building an Evidence Base in Complementary and Integrative Healthcare for Child & Adolescent Psychiatry”. In: Child Adolesc Psychiatric Clin N Am Vol. 22 #3 (2013) 509-529. Elsevier, Inc.
16. Saah TC, Garlow SJ, Rapaport MH, Edwards DM, Hale KL, Maddux, RE: “Anxiolytic Drugs” in Psychiatry, 4th Edition, A Tasman, J Kay, J Lieberman, M First and M Maj (eds). John Wiley & Sons, Ltd. (2014)

 

Books Edited or Written

1. Hales DJ, Rapaport MH: FOCUS, Psychiatry Review, “400 Self-Assessment Questions.” 2007; APPI Press

2. Hales DJ, Rapaport MH: FOCUS, Psychiatry Review, “400 All New Multiple Choice Questions.” 2011; APPI Press

3. Hales DJ, Rapaport MH, Moeller K: FOCUS, Maintenance of Certification (MOC) Workbook, “Major Depressive Disorder”, 2013; APPI Press

 

Book Reviews

1. Rapaport MH: “Panic disorder and its treatment. “New England Journal of Medicine, 1998: 330:1483-1484

 

Other Publications

1. Wolkowitz O, Rapaport MH: “Long-lasting behavioral changes following prednisone withdrawal.”
JAMA, 1989:261(12):173

2. Regier DA, Shore D, Rapaport MH, Prien R, Keith SJ: “NIMH bulletins and redundant publications.” Biol Psychiatry , 1991:29:307-308

3. Challakere K, Rapaport MH: “False positive HIV-ELISA results in a low-risk control population.” West J Med, 1993:159 (2): 214-215

4. Rapaport MH: Letter to the Editor re: “Diagnostic and substance specificity of carbon-dioxide-induced panic.” Am J Psychiatry, 1994:151 (2):292

5. Rapaport MH: Letter to the Editor re: “Missed psychiatric appointments: who returns and who stays away.” Am J Psychiatry, 1994:151(5):786

6. Zisook S, Rapaport MH, “Case history: major depressive disorder in a middle-aged female” Medical Age Publishing, Norwalk CT, 1997

7. Rapaport MH: Letter to the Editor re: “Inclusion/exclusion criteria of clinical trials.” J Clin Psychopharmacol, 1997:17(4):324

8. Rapaport MH: Letter to the Editor re: “Clinical differences between the generic and non-generic forms of clonazepam.” J Clin Psychopharmaco, 1997:17(5):424

9. Dolnak D, Rapaport MH, Hawthorne W: Letter to the Editor re: “Residential treatment for patients in crisis.” Psychiatr Serv, 1998:49(2): 246

10. Rapaport MH, Maddux RE, Delrahim KK: “Measuring quality of life in patients with panic disorder.” Psychiatric Times, 2003;1-2

11. Rapaport MH, Delrahim KK, Maddux RE: “Burden of phobias: Focus on health-related quality of life.” World Psychiatric Association: Evidence and Experience in Psychiatry, 2004;Vol.London: John Wiley & Sons Ltd. 2004

12.Culpepper L, Judd CR, Moller MD, Nemeroff CB, Rapaport MH, Ciraulo DA: “Clinicians on the front line: Active management of depression and anxiety in primary care.” JAPA, 2006;4:22

13. Freedman R, Lewis DA, Michels R, Pin DS, Schultz SK, Tamminga C, Patterson SL, McIntyre JS, Goldman HH, Yudofsky SC, Hales RE, Rapaport MH, Hales D, Krajeski J, Kupfer DJ, Badaracco MA, Scully JH Jr: “Conflict of Interest, Round 2.” Am J Psychiatry, 2006;163(9):1481-3

14. Rapaport MH: “Translating the evidence on atypical depression into clinical practice.” J ClinPsychiatry, 2007:68:(suppl 3):31-36

15. Rapaport MH. Response letter to Dr. Bernard Carroll, Neuropsychopharm, 2008 Sep:33(10) :2548. Epub 2007 Nov 14

16. Rapaport MH, Hales DJ: “The qualifications for recertification: An important, but evolving set of standards.” 2008; Editorial, ASCP Corner, J Clin Psychiatry, 69:11:1829-1830

17. Szeftel R, Hakak R, Meyer SE, Sulman-Smith H, Delrahim K, Rapaport MH: “Training psychiatric residents and fellows in a telepsychiatry clinic: A supervision model.” Academic Psychiatry, 2008;
32(5):393-399

18. Rapaport MH: “Future drugs for the treatment of depression: the need to look beyond monoamine systems.” In “Efficacy, safety, and tolerability considerations in the novel treatment of Major Depressive Disorder.” CNS Spectr (SUPPL), 2009:143:14-16

19. Rafin ZY, Pimstone DJ, Rapaport MH: “The Surgeon Who Operated on Himself” Current Psychiatry, 2011:10(2)53-58

20. Freeman MP, Rapaport MH, Editorial, “Omega-3 Fatty Acids and Depression: From Cellular Mechanisms to Clinical Care” American Society of Clinical Psychopharmacology Corner, J Clin Psychiatry, 2011:72(2)258-259

21. Dunlop BW, Rakofsky, JJ, Rapaport MH: “A Simple Question Answered: Adding Moderate-Dose Lithium does not Help Patients with Bipolar Disorder” Editorial, Am J of Psychiatry, 2013: 170(1) 9-11

 

Published Abstracts

1. Lucas PB, Hommer D, Kelsoe J, Rapaport MH, Pato C, Pickar D: “Effects of Caffeine Challenge in Schizophrenics.” APA 1987

2. Gillin JC, Shiromani PJ, Rapaport MH: “The Neurobiology of Sleep: Basic Concepts and Clinical Implications.” APA 1987

3. Rapaport MH, McAllister CG, Pickar D, Paul SM: “Immunological Changes in Schizophrenia.” ACNP 1987

4. Pato C, Wolkowitz O, Rapaport MH, Schulz SC, Pickar D: “Benzodiazepine Augmentation of Neuroleptic Treatment in Patients with Schizophrenia.” NCDEU 1988

5. Rapaport MH, Wolkowitz O, Kelsoe J, Pato C, Konicki P, Litman R, Pickar D: “The Beneficial Effects of Adjuvant Treatment with Nalmafene in Neuroleptic Stabilized Schizophrenic Patients.” ACNP 1988

6. Pato C, Schreiber J, Kelsoe J, Long R, Skea S, Manschreck T, Rapaport MH, Ginns E, Pickar D, Paul S: “Identification and Clinical Characterization of a Large Pedigree with a High Incidence of Chronic Psychosis.” ACNP 1988

7. Rapaport MH, McAllister CG, Nelson D, Pickar D, Paul SM: “Increased Levels of Soluble Interleukin-2 Receptors in Schizophrenic Patients.” APA 1989

8. Pato C, Schreiber J, Kelsoe J, Rapaport MH, Ginns E, Pickar D, Paul S: “Diagnostic Issues in a Pedigree with a High Incidence of Chronic Psychosis.” ICOSR 1989

9. Rapaport MH: “Immunological Findings in Schizophrenia.” World Congress of Psychiatry VIII 1989

10. Rapaport MH, McAllister CG, Paul SM, Pickar D: “The Effects of Clozapine Treatment on Mitogen Stimulated Lymphocyte Transformation in Schizophrenic Patients.” ACNP 1989

11. Pickar D, Litman RE, Rapaport MH, Konicki PE, Owen RR: “Longitudinal Pharmacology and Biological Studies of Schizoaffective Illness.” ACNP 1989

12. Kelsoe J, Rapaport MH, Stubblefield B, Winfield S, O’Malley K, Martin B, Ginns E: “Genomic Sequence and Linkage Studies of the Tyrosine Hydroxylase Gene in Manic Depressive Illness.” Winter Conference on Brain Research 1989

13. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Paul S: “The Analysis of CSF IL-1 and IL-2 from Controls and Schizophrenic Patients.” ACNP 1990

14. Rapaport MH, Risch SC, Golshan S, Gillin JC, Janowsky D: “The Effect of Physostigmine Infusions on Panic Disorder Patients.” NCDEU 1990

15. Rapaport MH: “A Review of Immune Findings in Schizophrenia.” World Psychiatric Congress 1992

16. Rapaport MH: “Immune Function in Psychiatric Disorders.” CINP 1992

17. Rapaport MH, Bazzetta J, Zisook S, Santucci T, Bruce S, Pickar D: “Evaluation of Functioning in Schizophrenia: Data Regarding the Validity of a New Scale.” APA 1993

18. Rapaport MH, Schmidt ME, Risinger R, Manji H: “Lithium Exposure and the Immune System.” ACNP 1993

19. Rapaport MH: “New Subtypes of Depression: Implications for Research.” World Psychiatric Congress 1993

20. Rapaport MH, Suminski M, Resovsky K, Goyette L, Greenfield D: “Preliminary Data about the source, Reasons for Rejection and Differences between Individuals Rejected and Enrolled in Protocols at a Clinical Research Center.” NCDEU 1993

21. Lucas J, Rapaport MH, Judd, LL: “The Neuropsychology of Social Phobia.” American Psychological Association 1994

22. Lucas J, Rapaport MH, Judd, LL: “Neurocognitive Functioning in Panic Disorder and Social Phobia.” 16th European Meeting of the International Neuropsychological Society, Angers, France 1994

23. Rapaport MH, Jeste DV, Lohr JB, Stein M: “Soluble Interleukin-2 Receptors in Psychiatric Illness.” CINP 1994

24. Rapaport MH, Stein MB: “Serum Interleukin-2 Receptor Levels in Generalized Social Phobia.” ADAA 1994

25. Judd LL and Rapaport MH: “The Social and Economic Burden of Mood Disorders.” CINP 1994

26. Rapaport MH: “A Review of Social Phobia.” NCDEU 1994

27. Rapaport MH, Frevert T, Babior S, Zisook S, Judd LL: “A Comparison of Demographic Variables, Symptom Profiles and Measurements of Functioning in Symptomatic Volunteers and in Outpatient Clinical Populations.” NCDEU 1994

28. Rapaport MH: “Soluble Interleukin-2 Receptors in Psychiatric Illness.” Symposium, “Zum Forderungsschwerpunkt der Stiftung Volkswagenwerk “Neuroimmundogie, Verhalten und Befinden,” Marburg, Germany 1994

29. Rapaport MH: “A Review of Atypical Neuroleptics.” H&CPI 1994

30. Jeste DV, Granholm E, Rapaport MH, Bazetta J, Harris MJ, Paulsen JS: “Late-Life Schizophrenia and Dementia.” APA 1995

31. Rubin HC, Rabin A, Gladsjo J, Kaplan RM, Rapaport MH: “Measuring Quality-of-Life in Panic Disorder.” APA 1995

32. Rapaport MH, Coccaro EF, Sheline YI, Holland PJ, Perse TL, Fabre LF: “Fluvoxamine Compared with Fluoxetine in Major Depression.” APA 1995

33. Rapaport MH, Bazzetta J, Jeste DV, Zisook S, Perry WB: “The Validation of the Scale of Functioning for Schizophrenic Subjects.” APA 1995

34. Rapaport MH, Zisook S, Frevert T, Seymour S, Judd L: “The Importance of Health Beliefs and Health Expectations in Determining Whether Individuals Seek Care as Outpatients or Symptomatic Volunteers.” NCDEU 1995

36. Rapaport MH, Coccaro LF, Sheline YI, Holland PJ, Perse TL, Fabre LF: “Fluvoxamine Compared with Fluoxetine in Major Depression.” ECNP, Venice, Italy 1995

37. Rapaport MH, Caligiuri MP, Lohr JB: “Association between Increased Serum Soluble Interleukin-2 Receptors and Disturbances in the Control of Motor Force in Schizophrenic Patients.” Society for Neurosciences 1995

38. Rapaport MH, Guylai L: “A Pilot Study of Cytokine and Soluble Interleukin-2 Receptor Levels in Symptomatic Bipolar Patients.” Second Symposium on the Neurovirology & NeuroImmunology of Schizophrenia and Bipolar Disorders, Stanley Foundation 1996

39. Rapaport MH, Jeste D: “Evidence of Differences in Immune Function in Older and Younger Schizophrenic Patients: Is This Age or a Function of Severity of Illness.” Second Symposium on the Neurovirology & NeuroImmunology of Schizophrenia and Bipolar Disorders, Stanley Foundation 1996

40. Rapaport MH, Guylai L, Whybrow P: “Immunomodulatory Effects of Lithium Carbonate in Normal Volunteers.” The Psychiatric Research Society 1997

41. Mendlowicz MV, Rapaport MH, Golshan S, Moraes TM: “ A Case-Controlled Study on the Socio-Demographic Characteristics of 53 Neonaticidal Mothers.” XXIInd International Congress on Law and Mental Health 1997

42. Gladsjo JA, Rapaport MH, McKinney RA, Rabin A, Auerbach MD, Judd LL: “Neuropsychological Functioning in Panic Disorder.” APA 1997

43. Auerbach MD, Rapaport MH, Gladsjo JA, McKinney RA, Oliver T, Judd LL: “A Comparison of the Efficacy of Alprazolam-Xr Plus Cognitive-Behavioral Therapy Versus Cognitive-Behavioral Therapy Plus Placebo for Acute Treatment at Three-Month Follow-Up.” APA 1997

44. Berlow RR, Mendlowicz MV, Montes J, Rapaport MH, Kelsoe JR, Akiskal HS: “Preliminary Analysis of a Self-Report Questionnaire of Affective Temperament.” APA 1997

45. McKinney RA, Gladsjo JA, Rapaport MH, Auerbach MD, Rabin A, Lucas J: “Implicit and Explicit Memory for Threatening Stimuli in Panic Disorder Patients.” APA 1997
46. Gladsjo JA, Rapaport MH, McKinney RA, Rain A, Auerbach MD, Judd LL: “Impact of Alprazolam on Neuropsychological Functioning in Panic Disorder.” APA 1997

47. Dolnak DR, Rapaport MH, Hawthorne WB: “Effect of Crisis Treatment on Functional Improvement.” APA 1997

48. Gekker M, Mendlowicz MV, Mecler K, de Moraes TM, Rapaport MH: “Newborn Murder in Maternity Wards: A Report of Three Cases and a Discussion on the Definition of Neonaticide.” APA 1997

49. Mendlowicz MV, Rapaport MH, de Moraes TM, Mecler K, Gekker M: “A Case-Control Study on the Socio-Demographic Characteristics of a Sample of Fifty-Five Neonaticide Women.” APA 1997

50. de Moraes TM, Mendlowicz MV, Rapaport MH, Mecler K, Gekker M: “A Descriptive Study of the Psychiatric Aspects of Fifty-Five Cases of Neonaticide.” APA 1997

51. Kelsoe JR, Sadovnick AD, Kristbjarnarson H, Bergesch P, Mroczkowski-Parker Z, Rapaport MH, Flodman P, Spence MA, Remick RA: “Support for the Dopamine Transporter as a Possible Susceptibility Locus for Bipolar Disorder.” APA 1997

52. Rapaport MH, Judd LL: “The Immune Immodulating Effects of Lithium in Normal Volunteers.” APA 1997

53. Rapaport MH, Judd LL: “The Characterization and Treatment of Patients with Minor Depression and SubsyndromalDepressive Symptoms.” APA 1997

54. Rapaport MH, Guylai L, Whybrow P: “The Immunomodulating Actions of Lithium in Normal Volunteers.” Symposium der Volkswagenstiftung 1997

55. Rapaport MH: “Psychosis, Motor Dysfunction, and Immune Activation.” Third Experts Meeting, Psychiatric Hospital, Ludwig-Maximilian-University, Munich, Germany 1997

56. Wolkow RM, Judd LL, Rapaport MH, Clary CM: “Quality of Life Differences in Sertraline and Placebo Responsive Panic Disorder Patients.” ACNP 1997

57. Rapaport MH, Caligiuri M: “Immune System Activation and Motor Dysfunction in Schizophrenia.” Society of Biol Psychiatry 1998

58. Rapaport MH, Pollack M, Wolkow R, Clary CM: “Panic Disorder and Response to Sertraline: The Effect of Previous Treatment with Benzodiazepines.” APA 1998

59. Pollack MH, Rapaport MH, Clary CM, Mardekian J, Wolkow R: “Sertraline Treatment of Panic Disorder: Response in Patients at Risk for Poor Outcome.” APA 1998

60. Rapaport MH, Wolkow R, Clary CM: “Quality of Life Difference: Sertraline and Placebo Panic Responders.” APA 1998

61. Pollack MH, Rapaport MH, Wolkow R, Clary CM: “Sertraline Treatment of Panic Disorder: Clinical Correlates of Treatment Response.” APA 1998

62. Rapaport MH, Caligiuri M: “Immune System Activation and Motor Dysfunction in Schizophrenia.” APA 1998

63. Rapaport MH, Judd LL: “Minor and Subsyndromal Depression and Their Treatment.” APA 1998

64. Rapaport MH: “Autoimmunity and OCD.” APA 1998

65.Judd LL, Rapaport MH: “Mood Disorders in Schizophrenia, One Disorder or Comorbid Disorders: Prevalence and Clinical Consequences.” International Academy for Biomedical and Drug Research Workshop 1998

66. Rapaport MH: “Childhood OCD and the Autoimmune Hypothesis.” CINP 1998

67. Rapaport MH, Gladsjo JA, Auerbach M, McKinney R, Hazen A, Judd LL, Davis J, Han T, Rabin A, Lucas J: “A Placebo-Controlled Trial of Alprazolam-XR in Conjunction with Cognitive Behavioral Therapy in the Treatment of Panic Disorder.” ADAA 1999

68. Dolnak DR, Rapaport MH: “Anxiety in Schizophrenia.” ADAA 1999

69. Gillin JC, Smith-Vaniz A, Zisook S, Stein M, Rapaport M, Kelsoe J: “Effects of Nefazodone on Sleep Nightmares and Mood in PTSD.” Sleep, 22(suppl):S277-S278, 1999

70. Landolt H-P, Schlosser A, Raimo E, Kelsoe RJ, Rapaport MH, Gillin JC: “Sleep Regulation in Depression: Effect of Selective REM Sleep Suppression by the Monoamine Oxidase Inhibitor (MAOI) Phenelzine on the Sleep EEG.” Sleep, 22(suppl):S250, 1999

71. Rapaport M, Pohl RB, Wolkow R, Rabin A, and Hackett E: “Safety of Sertraline in Long-Term Treatment of Panic Disorder: A Multicenter Study.” NCDEU 1999

72. Endicott J, Rapaport MH, Clary CM, O’Sullivan RL, Lane RM: “Sertraline and Quality of Life across Mood and Anxiety Disorders.” NCDEU 1999

73. Rapaport MH, Clary CM, Farfel G, Endicott J: “Patient-Rated Quality of Life: A Sensitive and Discriminating Outcome Measure in Mood and Anxiety Disorders.” ACNP 1999

74. Judd L, Rapaport MH, Yonkers K, Thase M, Kupfer D, Frank E, Tollefson G, Plewes J, Rush J: “Fluoxetine Treatment of Minor Depression: Acute and Continuation Results.” ACNP 1999

75. Kusumakar V, Greene P, Earl N, Ascher J, Monaghan E, Smoot T, Fouche N, Bowden C, Calabrese J, Post R, Sachs G, Suppes P, Gyulai L, Young T, Rapaport M: “Mood Stabilization with Lamotrigine in Rapid Cycling Bipolar Disorder: A Double-Blind, Placebo-Controlled Study.” ECNP 2000

76. Rapaport MH, Dolnak D, Caligiuri M: “Use of Objective Measures of Motor Function to Differentiate Olanzapine and Risperidone.” Society of Biol Psychiatry 2000.

77. Rapaport MH, Wang DR, Wang XF, Zhu WG, Chavez S, Dolnak D, Cole D: “The Identification of a Putative 60kda Autoantibody in Schizophrenia.” Society of Biol Psychiatry 2000

78. Dolnak DR, Rapaport MH, Caligiuri M, Golshan S: “Motor Dysfunction in Schizophrenia.” APA 2000

79. Rapaport MH, Tucker P, Farfel G, Clary C: “QOL Improvement with Sertraline Treatment of PTSD.” APA 2000

80. Dolnak DR, Rapaport MH, Caligiuri M, Lohr J, Golshan S: “A Prospective, Randomized, Double-Blind Study Contrasting Motor Dysfunction, Negative Symptoms and Functioning in Schizophrenic Patients Treated with Olanzapine and Risperidone.” NCDEU 2000

81. Rapaport MH, “PTSD and Quality of Life: Result of 64 Weeks of Sertraline Treatment.” ACNP 2000 Landolt HP, Kelsoe JR, Rapaport MH, Gillin JC: “Recurrence of Rem Sleep after Rapid Tryptophan Depletion in Depressed Patients Treated With Phenelzine.” SFN 2001

82. Rapaport MH, Londborg P, Heiser J, Wilcox C, Schwartz G: “Lamotrogine Demonstrates Long-Term Mood Stabilization in Manic Patients.” NCDEU 2001

83. Rapaport MH, Londborg P, Jeiser J, Wilcox C, Schwartz G: “Augmentation with the Selective NRI Reboxetine among Partial Responders to SSRI Therapy.” NCDEU 2001

84. Rapaport MH, Endicott J, Clary C: “PTSD and Quality of Life: Results across 64 Weeks of Sertraline Treatment.” NCDEU 2001

85. Rapaport MH, Clary C: “Quality of Life in Long-Term Sertraline Treatment in PTSD.” World Congress of Biol Psychiatry 2001

86. Rapaport MH, “Escitalopram Prevents Relapse in Depressive Episodes.” ACNP 2001

87. Rapaport MH, “Quality of Life in Anxiety and Depression Disorders.” NCDEU 2002

88. Rapaport MH, Bose A, Zheng H, Korotzer A: “Escitalopram Prevents Relapse of Depressive Episodes.” NCDEU 2002

89. Rapaport MH, “Quality of Life in Anxiety and Depressive Disorders.” XXIII CINP Congress 2002

90. Rapaport MH, “Efficacy of Paroxetine Controlled Release and Immediate Release Formulations in the Elderly.” ACNP 2002

91. Rapaport MH, Canuso CM, Loescher A, Lasser R, Gharabawi G: “Preliminary Results from the ARISe-RD (Risperidone Augmentation in Resistant Depression) Trial.” American Psychiatric Association 156th Annual Meeting 2003

92. Knapp RG, Rickels K, Rynn MA, Brawman-Mintzer O, Weihs KL, Shrivastava RK, Tilker HA, Sambunaris A, Patterson WM, Rapaport MH, Emanuel N, Hebert R: “Disaster Impact on GAD Research Population.” American Psychiatric Association 156th Annual Meeting, San Francisco, CA May 2003

93. Rapaport MH, Gharabawi G, Canuso C., Lasser R, Loescher A: “Preliminary Results from the ARISe-RD (Risperidone Augmentation in Resistant Depression ) Trial.” NCDEU 43rd Annual Meeting 2003

94. Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M: “Public Preferences for Health States with Schizophrenia and a Mapping Function to Estimate Utilities from Positive and Negative Symptom Scale Scores.” Elsevier B.V. 155 165, 2003

95. Rapaport MH, Canuso CM, Rouillon F, Leblanc J, Young AH, Loescher A, Bossie CA, Turkoz I, Gharabawi GM, and the ARISe-RD Study Group: “Treatment Augmentation with Risperidone for Patients with Resistant Depression.” APA 2004

96. Walling D, Rapaport MH, Rupnow MFT, Canuso CM, Gharabawi GM: “Improvement in Quality of Life with Risperidone Augmentation in Resistant Depression.” APA 200

97. Rapaport MH: “Emerging Treatment Options in Treatment-Resistant Mood and Anxiety Disorders.” APA 2004

98. Rapaport MH, Canuso CM, Rouillon F, Leblanc J, Young A, Loescher A, Bossie CA, Turkoz I, Gharabawi GM: “Results from the Arise-RD (Augmentation with Risperidone in Resistant Depression) Trial.” NCDEU 44th Annual Meeting 2004

99. Rapaport MH, Bose A, Saikali K: “Escitalopram Improves Somatic Symptoms of Depression.” NCDEU 44th Annual Meeting 2004

100. Rapaport MH, et al: “COX-2 Inhibitor Augmentation Therapy for Schizophrenia.” Biological Psychiatry 60th Annual Convention and Scientific Program 2005

101. Gertsik L, Moser F, Rapaport MH, et al: “Risperidone Augmentation of Treatment-Resistant Depression: Brain Metabolite Alterations Associated with Treatment Response,” Biological Psychiatry 60th Annual Convention and Scientific Program 2005

102. Thase ME, Rush JA, Rapaport MH, et al, “Fluoxetine Not Found to Increase Suicidality Over Placebo During Treatment of Adults with Minor Depressive Disorder.” Biological Society 60th Annual Convention and Scientific Program 2005

103. Howland RH, Nierenberg A, Rapaport MH: Poster, “Clinical Characteristics of Patients With Minor Depression.” APA 2005

104. Rapaport MH, Bresee K: “Cytokine Alterations in Medication-Stabilized Patients with Schizophrenia.” Society for Biological Psychiatry 61st Annual Meeting 2006

105. Anand R, Gharabawi G, Greist J, Rapaport MH, Sheehan D Poster: “A New Approach for Assessing Patients with Generalized Anxiety Disorder or Major Depression and Residual Symptoms.” American Psychiatric Association 159th Annual Meeting 2006

106. Glick ID, Rapaport MH, Ketter TA, Zisook S: “Clinical Psychopharmacology and Neurosciences: Keeping-up by Tailoring the Curriculum to the Constituency.” NCDEU 2006

107. Rapaport MH, Barbato LM, Heisterberg J, Yeung PP, Shapiro NA: “Efficacy and Safety of Bifeprunox versus Placebo in the Treatment of Patients with Acute Exacerbations of Schizophrenia.” American College of Neuropsychopharmacology 45th Annual Meeting 2006.

108. Rapaport MH, Koury MA, Hale KL, Bresee KJ: “The Beneficial Effects of Massage Therapy on Psychiatric and Biological Measures.” Society of Biological Psychiatry 62nd Annual Scientific Convention and Meeting 2007

109. Rapaport MH, Bresee KJ: “The Effects of Acute and Continuous Massage Therapy on the HPA Axis and Immune Function.” American College of Neuropsychopharmacology 2007

110. Rapaport MH, IsHak WW: “Quality of Life of Patients with Major Depression in a Natural Clinical Setting” Co-Chair, FOCUS Live Session, APA Annual Meeting, Washington, DC 2008

111. Rapaport MH, Hale KL, Koury MA, Shubov A, Bresee KJ: “The Role of Oxytocin, Vasopressin and Cortisol in the Beneficial Effects of Massage.” Society of Biological Psychiatry 2008

112. Turner N, Macfadden W, Anand R, Khanna S, Rapaport MH, Haskins T, Turkoz I, Alphs L: “Use of a Relapse Monitoring Board for Independent Assessment of the Primary End Point in an International Clinical Trial of Bipolar Disorder.” ISCTM Annual Meeting 2009

113. IsHak WW, Rapaport MH: “Quality of Life in Major Depressive Disorder in a Naturalistic Treatment Setting.” 49th Annual NCDEU Meeting 2009

114. Ereshefsky L, Jhee S, Phillips D, Peterson M, Ogasa M, Gertsik, Loebel A, Rapaport MH, “Assessment of the Maximum Tolerated Dose (MTD) of Lurasidone in Patients with Schizophrenia.” ACNP 48th Annual Meeting, Hollywood, FL, 2009

115. Rapaport MH, Bresee C, Schettler P, “The Biology of Massage: Implications for Psychiatry.” ACNP 49th Annual Meeting, Miami Beach, FL 2010

116. Wedel PC, Barlow C, Bleicher LS, Carter TA, Dearie AR, Defratis-robinson J, Drayer JI, Lee DM, Lorrain KI, Pires JC, Rapaport MH, Seehus CR, Schettler PJ, Stoveken BS, Treuner K, Young AH, “Compound Identified by Neurogenesis Platform Shows Promising Efficacy in Treatment of Patients with Major Depressive Disorder with Concomitant Generalized Anxiety Disorder.” Society of Neuroscience, 40th Annual Meeting, San Diego, CA 2010.

117. Treating Major Depressive Disorder by Creating Positive Expectations for the Future: A Study for the Efficacy of Future Directed Therapy (FDT) “51st Annual NCDEU Meeting, Boca Raton, FL, 2011

Rapaport MH, Little J, Ereshefsky L, Demartinis N, Targum S. Use of Audio-Digital Recordings for External Monitoring to Improve Subject Selection in a Schizophrenia Trial.” 51st Annual NCDEU Meeting, Boca Raton, FL, 2011

118. Rapaport MH, Hales D, Moeller K, “Innovations in Lifelong Learning for Psychiatrists: The Focus System”, 52nd Annual NCDEU Meeting, Phoenix, AZ, 2012.

119. Isofescu D, Gilmer W, Fan A, Gonenc A, Moore C, Randolph C, Rapaport MH, Deckersbach T, and Nierenberg A, Poster: “The Efficacy of Memantine for Cognitive Deficits in Euthymic Subjects with Bipolar Disorder”, 52nd Annual NCDEU Meeting, Phoenix, AZ, 2012.

120. Iosifescu D, Gilmer W, Fan A, Gonenc A, Moore C, Randolph C, Rapaport MH, Deckersbach T, and Nirenberg A, Poster: “The Efficacy of the Glutamate NMDA Receptor Antagonist Memantine for Cognitive Deficits in Euthymic Subjects with Bipolar Disorder” , ACNP 51st Annual Meeting, Hollywood, FL, 2012.